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The molecular epidemiology and mechanism of quinolone resistance of South African 
human isolates of Salmonella Typhi for the period 2003-2007, Salmonella Enteritidis, 
Salmonella Isangi and Salmonella Typhimurium for the period 2004-2006, received by 
the Enteric Diseases Reference Unit (EDRU) of the National Institute for Communicable 
Diseases was investigated. Molecular epidemiology was investigated using pulsed-field 
gel electrophoresis (PFGE) analysis for all four serotypes, as well as multiple-locus 
variable-number tandem-repeats analysis (MLVA) for Salmonella Typhi and Salmonella 
Typhimurium. Three probable mechanisms for quinolone resistance were investigated 
which included: amino acid mutations in the quinolone resistance determining regions 
(QRDRs) of DNA gyrase (gyrA/gyrB) and topoisomerase IV (parC/parE), active efflux 
of antibiotic out the bacterial cell and plasmid-mediated resistance encoded by qnr genes. 
For the period 2003-2007, 498 human isolates of Salmonella Typhi were received by the 
EDRU, of which 27 were resistant to nalidixic acid (MICs, ≥32 µg/ml). Only 19 
Salmonella Typhi quinolone-resistant isolates were available for analysis. For the period 
2004-2006, 329 human isolates of Salmonella Enteritidis, 1005 human isolates of 
Salmonella Isangi and 2624 human isolates of Salmonella Typhimurium were received 
by the EDRU. Of these isolates, 119 Salmonella Enteritidis, 143 Salmonella Isangi and 
532 Salmonella Typhimurium were invasive, nalidixic acid-resistant. Only 116 
Salmonella Enteritidis, 137 Salmonella Isangi and 516 Salmonella Typhimurium 
invasive, nalidixic acid-resistant isolates were available for analysis. For each respective 
serotype the isolates were genetically diverse as they could be differentiated into many 
 vi
PFGE types, suggesting that quinolone-resistant strains have emerged independently of 
one another for all four serotypes. The use of MLVA for Salmonella Typhi and 
Salmonella Typhimurium also illustrated the genetic diversity of the isolates by 
differentiating the isolates in various MLVA types. The investigation into the 
contributory mechanisms of resistance showed that an over-active efflux system in 
combination with mutations in both gyrA and parC play a major role in facilitating 
quinolone resistance in Salmonella Typhi, Salmonella Enteritidis and Salmonella Isangi. 
These very same mechanisms were also found to be responsible for the quinolone 
resistance in the majority of the Salmonella Typhimurium isolates along with the rarely 
isolated mechanism of resistance, a qnr plasmid. This is the first report of any kind 
identifying the presence of qnr genes in South African Enterobacteriaceae isolates. Our 
study also highlights the need for further work to establish the link amongst the various 
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Layout of Dissertation 
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(Chapter 7). A common reference section is presented, followed by six appendices, the 
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Chapter 1: Introduction 
 
1.1 Background 
Salmonella is the leading cause of food and water-borne disease worldwide, causing an 
estimated 16 million annual cases of gastroenteritis and/or enteric fever, resulting in five-
hundred thousand deaths. The majority of these infections are among young children and 
elderly adults in both developing and developed countries, impacting both socially and 
economically. Salmonella has also been identified as an important opportunistic pathogen 
affecting those individuals with human immunodeficiency virus (HIV) infection 
(Edgeworth, 2005). The genus Salmonella, named after D.E. Salmon an American 
bacteriologist and veterinarian who studied animal pathogens, can be divided into two 
species S. enterica and S. bongori. S. enterica can be further divided into seven 
subspecies assigned by Roman numerals. S. enterica subspecies Ι contains over two-
thousand described serotypes, which represent more than 99.5% of clinical isolates, are 
isolated from warm-blooded animals. The remaining six subspecies, Ι Ι, Ι Ι Ιa, Ι Ι Ιb, ΙV, 
V Ι and V Ι Ι, which represent less than 0.5% of clinical isolates, are isolated from cold-
blooded animals. This organism is capable of large community outbreaks of food-borne 
illness as well as nosocomial outbreaks. S. enterica is spread via contaminated food 
products usually of animal origin resulting in gastroenteritis, while serotypes Typhi and 
Paratyphi, causing typhoid fever and paratyphoid fever respectively, are spread directly 





S. enterica is a Gram-negative, facultative, rod-shaped bacterium in the same family as 
Escherichia coli, the family Enterobacteriaceae, commonly known as enteric bacteria.  
Most Salmonella strains are motile with peritrichous flagella, however, non-motile 
variants may occur occasionally. Most strains grow on nutrient agar as smooth colonies, 
2-4 mm in diameter.  Salmonella ferment glucose, use citrate as their sole carbon source, 
produce H2S during the fermentation process, are oxidase negative, reduce nitrates to 
nitrites and do not require sodium chloride (NaCl) to grow. Salmonella grow at 
temperatures between 8 and 45 degrees Celsius (ºC) and in a percentage hydrogen (pH) 
range of 4-9. Salmonella are heat sensitive and are usually killed at temperatures in of 
70ºC (Tindall et al., 2005). Although the principal habitat of the Salmonella is the 
intestinal tract of humans and animals, Salmonella has been isolated from contaminated 
environmental sources such as soil. Such sources support the growth of Salmonella if the 
aforementioned conditions are favourable. The Gram-negative S. enterica cell wall 
contains a thin peptidoglycan layer adjacent to the cytoplasmic membrane. In addition to 
the peptidoglycan layer, the Gram-negative cell wall also contains an additional outer 
membrane composed by phospholipids and lipopolysaccharides which face the external 
environment. The highly charged lipopolysaccharides translate a negative charge to the 
Gram-negative cell wall. The chemical structure of the outer membrane 
lipopolysaccharides is often unique to specific bacterial strains and is responsible for 
many of the antigenic properties of these strains (Gootz, 2006). 
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This antigenicity of S. enterica has aided with diagnostic or identifying applications. A 
serotyping application termed the Kauffman-White uses the three main antigenic factors 
to determine the isolates serotype phenotypically. Serotypes are identified using specific 
anti-sera to elicit an agglutination of highly specific somatic or cell wall antigens (O) 
which are heat stable and alcohol resistant, flagellar antigens (H) which are heat labile 
proteins and surface or envelope antigens (Vi) which only occur in three serotypes, 
Typhi, Paratyphi C and Dublin. A given serotype will contain a specific combination of 
O and H antigens, with possibly the occurrence of the Vi antigen (Kaufmann, 1966). 
 
1.3 Pathogenesis 
Salmonella infections occur when a pathogenic strain is ingested through contaminated 
source. Salmonella begin infection by systematically surviving the acidic pH of the 
stomach, which is dependant on the infectious dose, competing with the normal flora of 
the small intestine and then translocating across the intestinal mucosa to propagate in the 
antigen-sampling M cells of the Peyer’s patch as well as the draining mesenteric lymph 
nodes. The pathogenic effect of invading Salmonella on M cells is rapid post-infection as 
significant damage to the intestinal epithelium is observed. This includes the invasion of 
enterocytes, sloughing of large sections of epithelial cells and the penetration of large 
numbers of bacteria into underlying tissues. The diarrhoeal symptoms result from the 
inflammatory reaction that has been elicited in the small intestine due to the presence of 
invading bacteria. The presence of invading Salmonella causes host responses in the form 
of increasing the number of M cells, increasing the number of CD4+ cells, decreasing the 
number of CD8+ cells and activating the humoral and cellular divisions of the immune 
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system. The invading organisms enter the lymphatic system and interact with leukocytes 
which endeavour to kill the internalised bacteria using oxygen-independent mechanisms. 
Salmonella that survive disseminate via monocytes through the lymphatic system to the 
thoracid duct into the blood and finally to host sites such as the liver and bone marrow, 
from where disease symptoms may manifest as an invasive infection (Santos et al., 2003; 
Zhang et al., 2003; Shakespeare et al., 2005; Srikanth & Cherayil, 2007). 
 
1.4 Clinical Presentation 
Infections caused by Salmonella may result in gastroenteritis, bacteraemia, local 
infections, chronic carrier state or enteric fever.  The incubation period is approximately 
6-72 hours and diagnosis is made by isolating the organism from a food source or from 
the patient’s stool. Gastroenteritis is characterised by abdominal pain and loose, watery 
stools, low-grade fever and varying severity of nausea and vomiting (Bhan, et al., 2005). 
Bacteraemia is a manifestation of disease characterised by a prolonged fever and a 
positive blood culture, with symptoms of gastroenteritis occasionally present. Salmonella 
organisms can also infect any anatomical site producing local infections such as 
abscesses independently of any systemic illness (Shakespeare et al., 2005). Although an 
individual may recover from a Salmonella infection they may still excrete the causative 
organism in their faeces for up to year. This condition is called the carrier state and is 
especially prominent in typhoid fever. Enteric fever which is the most severe of all the 
types of clinical presentations is caused primarily by human specific serotypes, 
Salmonella enterica serotype Typhi, but can also be caused by Salmonella enterica 
serotype Paratyphi A, Salmonella enterica serotype Paratyphi B and Salmonella enterica 
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serotype Paratyphi C. Illness is characterized by prolonged fever, rose spots and malaise 
(Bhan, et al., 2005). 
 
1.5 Prevention 
Salmonella infections can be prevented by limiting the contact of humans to 
contaminated food and water. Municipalities should ensure adequate sewage disposal 
system and clean water supply. Education plays a big role in stemming the spread of 
infectious disease. The practice of good personal hygiene, good food hygiene and the 
eradication of the chronic carrier state will decrease the incidence of Salmonella 
infections (Le et al., 2004). Although vaccines for non-typhoidal Salmonella infections 
are still being assessed, enteric fever due to Salmonella Typhi can be prevented by 
immunisation. Vaccines are available in three variants and may confer immunity from 
infection for varying degrees of time ranging from 2-5 years. These vaccines if 
administered in areas of where the burden of disease is high (1000 infections per 100 000 




A varying number of antibiotics are used to treat infections due to Salmonella. 
Ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, ceftriaxone 
and azithromycin are the first choice antibiotics used to treat salmonellosis, but the 
fluoroquinolone ciprofloxacin has become the popular choice for treatment of invasive 
infection and enteric fever (Bhan et al., 2005). Treatment of gastroenteritis due to 
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Salmonella is not essential, as the antimicrobial therapy does not seem to decrease the 
duration or severity of the gastroenteritis. Rehydration with electrolytes and fluids is the 
recommended treatment in non-invasive or where enteric fever has not been diagnosed 
(Bertrand et al., 2006). Although ciprofloxacin is the treatment of choice for invasive 
disease and enteric fever it has been suggested that treatment with a combination of 
antibiotics such as ciprofloxacin and cefazolin may be useful in combating infection 
caused by antibiotic-resistant Salmonella strains (Mandal et al., 2004). 
 
 1.7 Quinolone Antibiotic Resistance 
The prototype for modern day quinolones, nalidixic acid, was discovered in 1962 as a by 
product of the formation of the anti-malarial drug chloroquine. The 1980s brought about 
the synthesis of the second-generation quinolones, the fluoroquinolones, including 
ciprofloxacin and levofloxacin (Zhanel et al., 2004). Quinolones are bactericidal and 
exhibit concentration-dependent killing. Quinolones enter bacteria through porins or 
directly through the lipid and cytoplasmic membrane (Nordmann & Poirel, 2005). The 
targets of quinolone activity are the bacterial deoxyribose nucleic acid (DNA) gyrase and 
topoisomerase IV, enzymes essential for DNA replication and transcription.  Antibiotics 
are critical in the management of typhoid fever. Various fluoroquinolones such as 
ciprofloxacin have become the routine treatment for typhoid fever. Internationally there 
has been a disturbing trend noted of increasing resistance to the quinolones and decreased 
susceptibility to fluoroquinolones in salmonellosis (Paterson, 2006). This resistance is 
thought to be driven by the selective pressure of exposure of the organism to 
antimicrobial agents during therapy. Resistance to quinolones limits drug selection for 
 6
treatment of infections as the organisms resistant to quinolones often are resistant to other 
classes of antimicrobials, either as a result of stepwise evolution of resistance mutations 
in target genes or due to the selection of an over-active efflux pump in combination with 
decreased outer membrane permeability (Giraud et al., 2006), which makes the 
management of infection due Salmonella, in particular Salmonella Typhi due its clinical 
implications, all the more difficult (Butt et al., 2003). 
 
Three major mechanisms have been described for the development of quinolone-
resistance in Salmonella (Jacoby, 2005). The first mechanism involves amino acid 
mutations in the quinolone resistance determining regions (QRDRs) of DNA gyrase 
(gyrA/gyrB) and topoisomerase IV (parC/parE) (Eaves et al., 2002; 2004): DNA gyrase 
is the primary target of quinolone antibiotics. Amino acid mutations in the QRDR of 
gyrA results in resistance to the non-fluorinated quinolone, nalidixic acid, while also 
resulting in reduced susceptibility to fluoroquinolones such as ciprofloxacin. Amino acid 
mutations at Ser-83 (to Phe, Tyr, or Ala) or at Asp-87 (to Gly, Asn, or Tyr) are the most 
frequently observed mutations in gyrA. Additional amino acid mutations in the QRDRs 
of parC, gyrB, and parE proteins, results in resistance to fluoroquinolones such as 
ciprofloxacin (Eaves et al., 2004; Hopkins et al., 2005). Although it is widely believed 
that quinolone resistance evolves in a stepwise manner as a result of initial mutation in 
the DNA gyrase genes, followed by mutations in the topoisomerase genes (Nordmann & 
Poirel, 2005), there are contrary reports that suggest that for Salmonella efflux 
mechanisms are primarily selected (Giraud et al., 2006).   
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The second mechanism for quinolone resistance in Salmonella is the active efflux of 
antibiotic from the bacterial cell. Efflux pumps are naturally present in bacteria and there 
function is to eliminate toxic compounds from the bacterial cell. Overproduction of efflux 
pumps results in removal of quinolones (and other antibiotics) from bacterial cells and 
contributes to the development of resistance (Saenz et al., 2004). The AcrAB-TolC efflux 
system is a major player with regards to quinolone resistance in S. enterica. AcrAB is a 
member of the resistance nodulation cell division family of transporters and is encoded 
by acrAB. The pump has three components: a transporter protein in the inner membrane 
(AcrB), a periplasmic accessory protein (AcrA), and an outer membrane channel (TolC). 
AcrB captures its substrates within the phospholipid bilayer and transports them into the 
external medium via TolC. Cooperation between AcrB and TolC is mediated by the 
periplasmic protein AcrA (Baucheron et al., 2002; Hopkins et al., 2005; Olliver et al., 
2005). Alterations in the outer membrane protein and lipopolysaccharide profiles of 
resistant Salmonella have been reported as the possible cause of decreased permeability 
of the outer membrane and in combination with an active efflux may result in a 
subsequent decreased accumulation of antibiotic (Giraud et al., 2000).  The involvement 
of the AcrAB-TolC efflux system in the development of quinolone resistance has been 
proven qualitatively through studies which have taken quinolone-resistant strains, 
inactivated their efflux systems, and then showed a resultant decrease in resistance (Chu 
et al., 2005). Inactivation of efflux systems have been performed through inactivation of 
genes coding for the efflux and through the use of efflux pump inhibitors such as 
β-Phe-Arg-naphthylamide (Saenz et al., 2004). Other researchers have shown the effect 
of an increased expression AcrA on the efflux system in fluoroquinolone-resistant 
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isolates using quantitative methods such as Western-blotting (Morgan-Linnell et al., 
2009). 
  
The third mechanism described for the development of quinolone resistance in 
Salmonella is that of plasmid mediated quinolone resistance. Three genes have been 
identified as those responsible for conferring resistance to quinolones. The pentapeptide 
repeat gene qnrA (Jacoby et al., 2003) is responsible for encoding a protein that protects 
DNA gyrase from inhibition by quinolones. The other pentapeptide repeat genes qnrB 
(Jacoby et al., 2006) and qnrS (Kehrenberg et al., 2006; Hopkins et al., 2007) have also 
been associated with conferring resistance to quinolones. The first qnr gene was isolated 
in 1998 from a Klebsiella pneumoniae isolate from Birmingham, Alabama, United States 
of America, and was called qnrA (Martinez-Martinez et al., 1998). Shewanella algae, an 
environmental species from marine and fresh water, was identified as its reservoir (Poirel 
et al., 2005). qnr genes have been found in various bacteria worldwide which include; 
Citrobacter freundii, Enterobacter species, Escherichia coli, Klebsiella pneumoniae and 
Providencia stuartii in the United States (Jacoby et al., 2003), Salmonella species in the 
United Kingdom (Hopkins et al., 2007)  and Shigella flexneri in Japan (Hata et al., 2005). 
 
1.8 Incidence of Quinolone-Resistant Salmonella 
Quinolone-resistant Salmonella has become a global burden with various countries 
reporting high rates of resistance to quinolones as well as reduced susceptibility to 
fluoroquinolones. In 1997 Herikstad et al. reported on the emergence of quinolone 
resistant Salmonella in the United States of America. Since then a number of reports have 
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surfaced of quinolone-resistant as well as multi-drug-resistant isolates. A report from 
Turkey where a random sample of a total number of 73 from various serotypes of 
Salmonella produced a quinolone resistance rate of 12.3% (Albayrak et al., 2004). From 
a sample of 261 non-typhoidal Salmonella (NTS) a Korean study reported a 1.8% 
increase in quinolone resistance to an overall 21.8% (Choi et al., 2005). A similar 
Taiwanese study reported a quinolone resistance rate of 69% (Su et al., 2004). National 
surveillance in Denmark revealed that over a five year period that the incidence of 
quinolone-resistant Salmonella enterica serotype Enteritidis had increased from 0.8% to 
8.5% (Mølbak et al., 2002) A retrospective study on 744 typhoid case isolates from 
Nigeria highlighted a 20% ciprofloxacin resistance rate, which is of concern considering 
that ciprofloxacin is the drug of choice for treatment of typhoid or enteric fever 
(Doughari et al. 2007). Butt et al. (2003) reported a case of ciprofloxacin treatment 
failure in Pakistan. Renuka et al. (2005) reported on high-level ciprofloxacin resistance in 
Salmonella enterica serotype Typhi in India, questioning whether or not fluoroquinolones 
should be considered as the first line of treatment for enteric fever. A study concentrating 
on invasive isolates for the years 1997-2001 from Northern India suggested that multi-
drug resistant isolates were on the increase (Gautam et al., 2002). These infections may 
be locally acquired or imported highlighting the global need for reviewed treatment 
strategies for salmonellosis.  In South Africa nalidixic acid resistance incidence rates 
have consistently remained around 23% for all Salmonella serotypes and resistance to the 




1.9 Molecular Typing of Salmonella Species 
Phenotypic typing based on biochemical and serological properties is the traditional 
method being used to differentiate between strains but current typing methods are based 
on the characterisation of the genetic traits of the organism by analysis of chromosomal 
or plasmid DNA. The use of pulsed-field gel electrophoresis (PFGE) analysis as a basis 
of identification of clones in Salmonella, is accepted as the gold-standard for typing 
Salmonella and has proven to be highly discriminatory when applied to most serotypes 
(Liu et al., 2003). PFGE is helpful for the investigation of clonal relationships between 
and within serotypes (Ribot et al., 2006). 
 
 PFGE differs from standard gel electrophoresis in the following respects. Standard gel 
electrophoresis employs a uniform electrical field in one direction which allows 
separation of DNA fragments up to 50000 base pairs (bp) in size. For DNA fragments 
>50000bp, the sieving action of agarose or polyacrylamide gel is lost because the DNA 
fragments will then not enter the gel matrix or just run as an resolved smear. PFGE 
allows one to overcome this problem and separate very large DNA fragments. This is 
achieved by employing an electrical field that regularly changes direction, called a 
contour-clamped homogenous electric field, throughout an agarose gel run. When such a 
pulsing electrical field is applied, DNA molecules move through the pores in a snake-like 
fashion, facilitating the separation of large DNA fragments. The choice of restriction 
enzyme for digestion of genomic DNA into several DNA fragments is very important. 
Rare cutting restriction enzymes are used to produce a limited number of large fragments. 
Usually a single enzyme is used, as a combination of enzymes can produce too many 
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small fragments. Usually enzymes with 6 to 8bp recognition sequences are used, as they 
will cut less frequently compared to enzymes with shorter base-pair recognition 
sequences. For PFGE analysis, bacterial cells are first immobilized in agarose blocks. 
This is followed by the digestion of DNA, all occurring within the confines of an agarose 
block which protects the genomic DNA from any random breaks. This ensures that the 
resulting DNA fragmentation pattern is the direct result of the occurrence of the digestion 
of the genomic DNA with the restriction enzyme (Reed et al., 2003). 
 
Other methods such as Phage typing (PT) is a classical method traditionally used for 
subtype determination of Salmonella but has limited discriminatory power and requires 
specialized phage collections that are available to only a few reference laboratories. 
Plasmid profiling, single-enzyme ribotyping, and random amplified polymorphic DNA 
(RAPD) analysis also have limited discriminatory power for Salmonella (Kim et al., 
2006). Like PFGE, two-enzyme ribotyping has been shown to have a greater 
discriminatory power but just like PFGE is also labour-intensive (Liu et al., 2003). A 
relatively newer genotypic typing method called multiple-locus variable-number tandem-
repeats (VNTRs) analysis (MLVA) has been established for a number of Salmonella 
serotypes (Lindstedt et al., 2003; Liu et al., 2003; Boxrud et al., 2007). MLVA is a 
multiplex polymerase chain reaction (PCR) based typing method designed to analyse 
fragment sizes which contain a variable number of tandem repeat sequences. This method 
is rapid and highly reproducible with greater discriminatory power (Lindstedt, 2005).  
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The MLVA technique was made possible through genome sequencing projects which 
revealed that a high percentage of microbial genomic DNA consists of repeats, where 
DNA motifs exist in multiple copies (Lindstedt et al., 2003). These repeats are referred to 
as variable-number tandem-repeats (VNTRs). They are located throughout the genome of 
bacteria and consist of short nucleotide sequences that are repeated in tandem. Individual 
strains within a bacterial species often maintain the same sequence element but with 
different copy numbers. The variation in copy number is caused by slipped-strand 
mispairing during DNA replication. Since sequence homology exists between strains in 
the flanking region of the VNTR locus, universal PCR primers can be used to amplify the 
locus from all strains of a particular species. Variations in copy number of a repeat 
sequence among individual strains can then be translated into different sized PCR 
products. To apply MLVA as a genotypic tool, one needs to analyze multiple VNTR loci, 
of which 3 to 8 loci are typically analyzed. Each VNTR locus is targeted by a specific 
pair of PCR primers. All the primer pairs are usually combined into a single multiplex-
PCR, resulting in the amplification of multiple products. These products are then 
electrophoretically size separated to produce a DNA fingerprint pattern. Each individual 
strain of bacteria will produce a unique pattern. The conventional method of MLVA 
employs agarose gel electrophoresis and ethidium bromide staining to visualize a DNA 
banding pattern, followed by capturing an image of the patterns (Lindstedt et al., 2003). 
 
Automated MLVA employs capillary electrophoresis of fluorescently labeled PCR 
products. The labeling of PCR product occurs via PCR primers which are labeled with 
distinctive fluorescent dyes (fluorophores). Numerous fluorophores exist, so each VNTR 
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locus can be labeled with a unique fluorophore. This allows detection and classification 
of multiple PCR products in a single reaction. Capillary electrophoresis of PCR products 
is performed in the same genetic analyzers which perform automated DNA sequencing. 
The electrophoresis process moves PCR products past a laser beam which excites the 
fluorophores, releasing light of distinctive colours (fluorescence) which are detected and 
translated into detection of specific PCR products. PCR products are also automatically 
sized via comparison to internal size standards. MLVA results are reported as a MLVA 
allele profile. For example, where 5 VNTR loci are analyzed, a strain could be defined by 
the MLVA allele profile '254-330-422-188-550', where the values represent the size (in 
base pairs) of the 5 loci (PCR products) (Lindstedt, 2005). Although MLVA is an 
advance in terms of genotyping, a combination of typing methods or the use of one 
method to supplement the other is seen as the best practise to achieving an accurate result 
(Liu et al., 2003). 
 
1.10 Aim and Objectives of the Study 
The aim of the research presented in this dissertation was to describe the mechanism of 
resistance and molecular epidemiology of invasive, quinolone-resistant non-typhoidal 
Salmonella enterica serotypes Typhimurium, Enteritidis and Isangi causing infections in 
South Africa for the years 2004-2006 and the typhoid causing Salmonella enterica 
serotype Typhi isolates causing infections in South Africa for the years 2003-2007. The 
objectives were as follows: 
• To investigate strain relatedness and cluster formation by PFGE and MLVA for each of 
the above Salmonella enterica serotypes; 
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• To investigate the presence and contribution of amino acid mutations in the QRDR to 
quinolone resistance in the above Salmonella serotypes by PCR and nucleotide 
sequencing; 
• To investigate the involvement of the phenotypic expression of an over-active efflux 
pump system in quinolone resistance in the above Salmonella serotypes, by means of 
doubling agar dilution minimum inhibitory concentration (MIC) test in the presence of β-
Phe-Arg-naphthylamide, an efflux pump inhibitor ; 
• To investigate the involvement of plasmid mediated quinolone resistance through the 
identification and characterization of the qnr genes by PCR and nucleotide sequencing. 
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Chapter 2: Materials and Methods 
 
2.1 Bacterial Isolates 
 
Three-thousand and fifteen invasive Salmonella isolates were received at the Enteric 
Diseases Reference Unit (EDRU) of the National Institute for Communicable Diseases 
(NICD), of the National Health Laboratory Service, Sandringham, South Africa, between 
2004 and 2006 as part of ongoing surveillance for salmonellosis.  An invasive isolate was 
deemed one that had been isolated from a normally sterile site (e.g. blood culture, 
cerebrospinal fluid, pleural fluid or joint fluid) from patients admitted to hospitals 
throughout South Africa. Of the three-thousand and fifteen invasive isolates, eight 
hundred and sixty-two isolates were resistant to the quinolone antibiotic, nalidixic acid, 
(MIC, ≥32 μg/mℓ) as determined by EDRU staff using Etest® strips (AB Biodisk, Solna, 
Sweden). 
 
Four Salmonella serotypes contributed to the majority (818/862; ≈ 94%) of the invasive, 
nalidixic acid-resistant isolates received by the EDRU from 2004-2006. Salmonella 
Typhi contributed seventeen isolates, to which isolates from years 2003 and 2007 were 
added for the purpose of this study to result in a total of twenty-seven Salmonella Typhi 
isolates. Only nineteen of the twenty-seven Salmonella Typhi quinolone-resistant isolates 
were available for analysis. The NTS Salmonella isolates were dominated by three 
serotypes, Salmonella Enteritidis (329), Salmonella Isangi (1005) and Salmonella 
Typhimurium (2624). Most isolates (667/818; ≈ 82%) were received from hospitals in 
 16
and around the province of Gauteng with the remaining isolates (≈ 18%) received from 
hospitals from other provinces in South Africa. For the period 2004-2006, three-hundred 
and twenty-nine human isolates of Salmonella Enteritidis, one-thousand and five human 
isolates of Salmonella Isangi and two-thousand six-hundred and twenty-four human 
isolates of Salmonella Typhimurium were received by the EDRU. Of these isolates, 
Salmonella Enteritidis contributed one-hundred and nineteen, Salmonella Isangi one-
hundred and forty-three, and Salmonella Typhimurium five-hundred and thirty-two 
isolates, for a total of seven-hundred and ninety-four invasive, nalidixic acid-resistant 
isolates. Only one-hundred and sixteen Salmonella Enteritidis, one-hundred and thirty-
seven Salmonella Isangi and five-hundred and sixteen Salmonella Typhimurium invasive, 
nalidixic acid-resistant isolates were available for analysis. Due to time and financial 
constraints all molecular analysis could not be performed on every isolate. Pulsed-field 
gel electrophoresis was performed on all available isolates but for the subsequent test 
each isolate was assigned a number and a random number table was used to randomly 
select isolates for further analysis. 
 
2.2 Pulsed-Field Gel Electrophoresis (PFGE) 
 
Salmonella embedded in agarose blocks were prepared using a previously described 
procedure with some adaptations (Ribot et al., 2006). Bacterial cultures were grown 
overnight on 5% Sheep blood agar plates [Diagnostic Media Products, National Health 
Laboratory Service, Johannesburg, South Africa (DMP)] and incubated at 37ºC. A third 
of the bacterial culture was resuspended into 800µl of cell suspension buffer (Appendix 
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A) and adjusted to a cell concentration turbidity of ≈ 0.7 using Microscan Turbidity 
Meter (Dade Behring, California, USA). Proteinase-K (Appendix A), 20µl, was added to 
200µl of the bacterial suspension, gently mixed and incubated at 37ºC for 5 minutes. Two 
hundred and eighty microliters of 1% SeaKem Gold® (Cambrex Bio Science, Rockland, 
USA): 1% sodium dodecyl sulphate (SDS) (Appendix A) was mixed with bacterial 
suspension, and immediately poured into reusable plug moulds (Bio-Rad Laboratories, 
California, USA) and allowed to solidify (≈10 minutes). To lyse the bacterial cells, the 
agarose plugs were removed from the moulds and transferred to an appropriately labeled 
tube containing 5ml cell lysis buffer (Appendix A). The tubes containing the agarose 
plugs were incubated for 2 hours in a 55°C shaker water bath with constant agitation 
(70rpm). To wash the plugs, the tubes were removed from the water bath and the lysis 
buffer decanted. The plugs were washed at 50°C in the water bath, in 15ml sterile 
deionized water (preheated to 50°C). The water was decanted and followed by four 
washes with sterile TE (Appendix A) buffer at 50°C. 
 
For bacterial DNA digestion, the plug was removed from the TE buffer and thin (1-2mm) 
slices of the agarose plugs were cut and added to a new tube containing restriction 
enzyme buffer called H-buffer (Roche Diagnostics, GmbH, Mannheim, Germany). The 
plugs were incubated at 37°C for 15 minutes. The H-buffer was removed and 
30U/sample XbaI (Roche Diagnostics GmbH, Mannheim, Germany) restriction enzyme 
added and incubated for three hours at 37°C. The restriction enzyme was removed from 
the tubes and 0.5Х TBE buffer (Appendix A) was added to the plugs and incubated for 5 
minutes at room temperature. The plugs were removed from the TBE buffer, loaded onto 
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the bottom of the comb teeth and allowed to air dry for 5-10 minutes. The reference strain 
CDC-H9812 Salmonella enterica Branderup (Salmonella Branderup) was included on all 
gels as a method of quality control and validation (Hunter et al., 2005). Plugs were 
attached onto a comb, placed in a gel casting tray and allowed to air-dry for 15 minutes 
before pouring 1% SeaKem Gold® agarose (Appendix A) into the casting tray and 
allowing to solidify (≈ 25 minutes). The gel was then loaded into the electrophoresis 
chamber of a contour-clamped homogenous electric field (CHEF-DR) apparatus (Bio-
Rad) containing 0.5Х TBE (± 3 liters) cooled to a temperature of 12°C and subjected to 
the following electrophoresis conditions for a run-time of 21 hours: 
CHEF-DR ΙΙ: Initial A time 2.2 seconds, Final A time 63.8 seconds, Start ratio 1.0, 
Voltage 200 volts. CHEF-DR ΙΙΙ: Initial A time 2.2 seconds, Final A time 63.8 seconds, 
Start ratio 1.0, Voltage 6 volts/centimeter, Angle included 120°. 
On completion of electrophoresis the gel was stained using an ethidium bromide solution, 
(Appendix A) for 30 minutes, gently agitated (12-15rpm) on a Sea-Saw Rocker™ (Stuart 
Scientic, Stone, Staffordshire, United Kingdom). The staining was followed by a 
destaining in 500ml deionized water for 20 minutes. The image was captured on the Gel 
Doc Quantity One documentation system (Bio-Rad) and saved as an uncompressed TIFF 
image (*.tif) for analysis with the BioNumerics™ (version 5.1) software program 
(Applied Maths, Sint-Martens-Latem, Belgium). All test patterns were normalized 
against the pattern of the Salmonella Braenderup reference standard. Cluster analysis of 
the patterns using the unweighted pair group method with arithmetic averages (UPGMA) 
resulted in the calculation of hierarchical tree-like structures (dendrograms), with analysis 
of banding patterns incorporating the Dice-coefficient at an optimization setting of 0.5% 
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and a position tolerance setting of 1.5%.  Seperate dendrograms were created for all the 
test isolates from each serotype that being, Salmonella Enteritidis, Salmonella Isangi, 
Salmonella Typhi and Salmonella Typhimurium. A PFGE type was defined as a unique 
PFGE pattern at 90% on the dendrogram. A PFGE cluster was defined as a group of two 
or more patterns at ≥90% similarity on the dendrogram. A PFGE type may itself be a 
cluster. 
 
2.3 Preparation of Crude Bacterial DNA 
 
A small loopful of bacteria (2 to 4 colonies) cultured on 5% sheep blood agar (DMP) was 
resuspended into 400µl of TE and boiled at 95°C for 20 minutes. The suspension was 
then centrifuged at 12000 rpm for 3 minutes and the resulting supernatant (crude DNA 
preparation) was used as a template for PCR. 
 
2.4. Multiple-Locus Variable-Number Tandem-Repeats Analysis (MLVA) 
 
2.4.1 MLVA: Salmonella Typhi 
 
To supplement the Salmonella Typhi PFGE outputs a second genotypic analysis method, 
MLVA was used to further analyze selected strains. MLVA was based on three VNTR 
gene loci (TR1, TR2 and TR3) as previously described (Liu, et al. 2003). Analysis of the 
selected strains employed the previously described method with a few adaptations. The 
previously described method utilized manual agarose gel electrophoresis analysis; 
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whereas this revised analysis method incorporated automated capillary electrophoresis of 
fluorescently labelled PCR products. A positive control Salmonella Typhi strain 
NCTC8385 was used a reference. The makeup of PCR primers used to amplify VNTR 
loci are shown in Appendix B1. The forward primer for each locus was labelled with a 
distinctive fluorescent dye (Applied Biosystems, Foster City, CA, USA). The reverse 
primer for each locus was unlabelled (Inqaba Biotechnical Industries, Hatfield, South 
Africa). Each VNTR locus was amplified in a separate PCR of 25µl final volume 
containing 1µl crude bacterial DNA, 2mM MgCl2, 0.5µM of each primer, 200µM 
deoxynucleotide triphosphates (Bioline, London, United Kingdom), 1 U Super-Therm 
Gold DNA polymerase (Southern Cross Biotechnology, Cape Town, South Africa) and 
1× Super-Therm Gold DNA polymerase buffer (Southern Cross Biotechnology). Thermal 
cycling was conducted using an i-Cycler (Bio-Rad) thermal cycler using the following 
run parameters: hot start at 95°C proceeding to 95°C for 2 minutes , 25 cycles at 95°C for 
75 seconds, 55°C for 75 seconds and 72°C for 75 seconds, with a final holding step at 
4°C. The three resultant PCR products were pooled as follows: 2µl of TR1 + 2µl of TR2 
+ 6µl of TR3. This pooled mixture was then diluted 1:40 in deionized water. Two 
microliters of this diluted mixture was then mixed with 0.7µl of GeneScan 600 LIZ size 
standard (Applied Biosystems) and 7.5µl of Hi-Di formamide (Applied Biosystems). 
This 10µl mixture was then incubated at 95°C for 3 minutes and cooled to room 
temperature before being subjected to capillary electrophoresis using an Applied 
Biosystems 3130 Genetic Analyzer. Electrophoresis was performed through POP-7 
polymer (Applied Biosystems) at a running voltage of 15 kV for 25 minutes at a 
temperature of 60°C and an injection voltage of 15 kV for 8 seconds. Raw data was 
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captured and analyzed using GeneMapper (version 4.0) software (Applied Biosystems) 
which identified each VNTR locus by its distinctive colour (fluorescence) and 
automatically sized the gene product via comparison to the internal size standard. The 
resulting fragment sizes were binned into alleles, entered into BioNumerics™ (version 
5.1) software program (Applied Maths) and a dendrogram constructed using the 
Euclidean distance-coefficient and the Ward algorithm. A MLVA type was defined by a 
unique MLVA allelic profile. For example MLVA type 23 represented the MLVA allele 
profile 234-443-566 which defined a 234bp PCR product for TR1, a 443bp PCR product 
for TR2 and a 566bp PCR product for TR3. 
 
2.4.2 MLVA: Salmonella Typhimurium 
 
To supplement the Salmonella Typhimurium PFGE outputs a second genotypic analysis 
method, MLVA was used to further analyze selected strains. MLVA was based on five 
VNTR gene loci (STTR3, STTR5, STTR6, STTR9 and STTR10-pl) as previously 
described (Lindstedt, et al. 2003). Analysis of the selected strains employed the 
previously described method (Lindstedt, et al. 2004) with a few alterations. This analysis 
method incorporated automated capillary electrophoresis of fluorescently labelled PCR 
products. The makeup of PCR primers used to amplify VNTR loci are shown in 
Appendix B2. The forward primer for each locus was labelled with a distinctive 
fluorescent dye (Applied Biosystems). The reverse primer for each locus was unlabelled 
(Inqaba Biotechnical Industries). The primers were multiplexed in two solutions using the 
Qiagen PCR multiplex Kit (Southern Cross Biotechnology) in a total of 50µl as per the 
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manufacturer’s instructions. Multiplex primer mix 1 (M1) consisted of: 10 pico mol 
(pmol) of the STTR6 and STTR3 primer pairs and Multiplex primer mix 2 (M2) 
consisted of: 10 pmol of the STTR9, STTR5, STTR10 primer pairs. Thermal cycling was 
conducted for both multiplex solutions using an i-Cycler (Bio-Rad) thermal cycler, under 
the same cycling conditions of 95°C for 15 minutes, proceeding to 25 cycles of 94°C for 
30 seconds, 63°C for 90 seconds and 72°C for 90 seconds and a final holding step at 72 
°C for 10 min. Prior to electrophoresis the two separate PCR products were pooled in the 
following manner: 10 µl of M1+2.5 µl of M2 were mixed and 87.5µl of deionized water 
was added to result in a total of 100 µl. Then 1µl of the pooled solution was mixed with 
0.7µl of GeneScan 600 LIZ size standard (Applied Biosystems) and 12µl of Hi-Di 
formamide (Applied Biosystems). This ≈14µl mixture was then incubated at 95°C for 3 
minutes and cooled to room temperature before being subjected to capillary 
electrophoresis using an Applied Biosystems 3130 Genetic Analyzer. Electrophoresis 
was performed through POP-7 polymer (Applied Biosystems) at a running voltage of 15 
kV for 35 minutes at a temperature of 60°C and an injection voltage of 15 kV for 5 
seconds. Raw data was captured and analyzed using GeneMapper (version 4.0) software 
(Applied Biosystems) which identified each VNTR locus by its distinctive colour 
(fluorescence) and automatically sized the gene product via comparison to the internal 
size standard. The resulting fragment sizes were binned into alleles according to their 
repeat sizes, entered into BioNumerics™ (version 5.1) software program (Applied 
Maths) and a dendrogram constructed using the Euclidean distance-coefficient and the 
Ward algorithm. A MLVA type was defined by a unique MLVA allelic profile. For 
example MLVA type E represented the MLVA allele profile 160-248-342-355-390 
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which defined a 160bp PCR product for STTR9, a 248bp PCR product for STTR5, a 
342bp PCR product for STTR6, a 355bp PCR product for STTR10-pl and a 390bp PCR 
product for STTR3. 
 
2.5 Polymerase Chain Reaction (PCR) and Sequencing 
 
2.5.1 Quinolone Resistance Determining Region (QRDR) 
 
PCR was used to amplify the QRDR of gyrA, gyrB, parC and parE using previously 
described methods (Eaves et al., 2004). Primers (Appendix C1) were synthesized by 
Inqaba Biotechnical Industries. PCR was conducted using an i-Cycler thermal cycler 
(Bio-Rad) programmed for thermal cycling for 30 cycles, included a denaturation step of 
95ºC for 1 minute, a primer annealing step for 1 minute (52ºC for gyrA, 55ºC gyrB, 58ºC 
parC and 57ºC parE) and a primer extension step at 72ºC for 30 seconds. PCR reagents 
listed in Appendix C1. PCR products were purified using QlAquick® PCR purification 
Kits (Southern Cross Biotechnology) or MSB® Spin PCRapace purification Kits 
(Invitek, GmbH, Berlin, Germany). The 16SrRNA gene was targeted as an internal 
amplification control as all bacterial strains contain this gene in there genome. A no 






2.5.2 Plasmid Genes (qnr) 
 
PCR was used to screen for three previously described qnr genes, qnrA, qnrB and qnrS, 
using previously described methods (Jacoby, et al. 2003; Jacoby, et al. 2006; Hopkins, et 
al. 2007).  Primers (Appendix C2) were synthesized by Inqaba Biotechnical Industries. 
PCR was conducted using an i-Cycler thermal cycler (Bio-Rad) programmed for thermal 
cycling for qnrA: 30 cycles, included a denaturation step of 94ºC for 1 minute, a primer 
annealing step of 57ºC for 1 minute and a primer extension step at 72ºC for 1 minute; and 
qnrB and qnrS: 32 cycles, included a denaturation step of 94ºC for 45 seconds, a primer 
annealing step of 53ºC for 45 seconds and a primer extension step at 72ºC for 1 minute. 
PCR reagents listed in Appendix C1. PCR products for any resultant positive qnr gene 
were purified using QlAquick® PCR purification Kits (Southern Cross Biotechnology) or 
MSB® Spin PCRapace purification Kits (Invitek). A positive control was not used as 
none were available. The 16SrRNA gene was targeted as an internal amplification control 
as all bacterial strains contain this gene in there genome. A no template control was also 
used. 
 
2.5.3 Detection of Positive PCR Reactions 
 
Three microliters of PCR reaction product were mixed with 2µl of loading buffer 
(Appendix C3) and loaded into wells of a 1.2% agarose gel (w/v) to which ethidium 
bromide had been added (Appendix C3). Three microliters of a 100 base pair DNA size 
marker, HyperLadder IV [Bioline (Celtic Molecular Diagnostics, Cape Town, South 
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Africa)] was added to the gel. Electrophoresis was performed at 140 volts for 45 minutes 
in a running buffer (Appendix C3) and the resulting DNA fingerprint pattern was 
captured on the Gel Doc Quantity One documentation system (Bio-Rad) and saved as an 




For DNA sequencing, purified PCR product was used as template in a PCR cycle 
sequencing reaction using the ABI Prism® Big-Dye Terminator version 3.1 cycle 
sequencing kit as per manufacturer’s instruction (Applied Biosystems). PCR reagents 
listed in Appendix C4. PCR was conducted using an i-Cycler thermal cycler (Bio-Rad) 
programmed for thermal cycling with and initial denaturation at 95ºC for 2 minutes 
proceeding to 25 cycles of, a denaturation step of 95ºC for 50 seconds, a primer annealing 
step of 50ºC for 50 seconds and a primer extension step at 60ºC for 4 minutes. Cycle 
sequencing products were applied to a DyeEx™ 2.0 Spin Kit as per manufacturer’s 
instruction (Southern Cross Biotechnology) and spun through a filtered column. The 
filtered sample was then vacuum-dried in Speed Vac Concentrator vacuum centrifuge 
(Savant, GMI Incorporated, Minnesota, United States of America) for an hour, 
reconstituted in 15µl of Hi-Di formamide (Applied Biosystems). This mixture was then 
incubated at 95°C for 3 minutes and cooled to room temperature and subsequently 
analyzed on an Applied Biosystems 3130 Genetic Analyzer and a sequence was 
determined. Sequences resulting from the analysis of the QRDR samples were compared 
to previously PUBMED published sequences 
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(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide) to determine mutations using 
BioEdit version7.5 and the pairwise comparison tool EMBOSS 
(http://www.ebi.ac.uk/emboss/align/) while sequences resulting from qnr positive PCR 
were confirmed using PUBMED Nucleotide BLAST 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide).  
2.6 Doubling Agar Dilution Minimum Inhibitory Concentration (MIC) and Efflux 
Pump Inhibition 
 
Selected strains were subjected to doubling agar dilution MICs for nalidixic acid and 
ciprofloxacin as previously described by the Clinical and Laboratory Standards Institute 
(CLSI) (CLSI, 2006). The MIC breakpoints used were those recommended by the CLSI. 
These were defined as strains exhibiting an MIC ≤16µg/ml nalidixic acid were deemed 
susceptible and those strains exhibiting an MIC ≥32µg/ml were deemed resistant. 
Ciprofloxacin breakpoints, those strains exhibiting an MIC ≤1µg/ml were deemed 
susceptible, strains exhibiting an MIC =2µg/ml were deemed intermediately resistant and 
strains exhibiting and MIC ≥4µg/ml were deemed resistant (CLSI, 2006). These 
breakpoints were adjusted in both increasing and decreasing fold values as to determine 
the exact MIC for the test isolates. The extra dilutions ranged from 1µg/ml to 512µg/ml 
for nalidixic acid and from 0.0625µg/ml to 16µg/ml ciprofloxacin. These agar dilution 
MICs were repeated within the presence of an efflux pump inhibitor (EPI), namely 
β-Phe-Arg-naphthylamide. Prior to performing efflux pump inhibition tests, a pilot study 
was performed to determine the appropriate concentration of EPI that could be used 
which not limit, inhibit or interfere normal growth of the bacteria. A concentration of 
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40µg/ml β-Phe-Arg-naphthylamide was found to be suitable. This concentration fell 
within a previously tested range (Baucheron, et al. 2002). A control strain Escherichia 
coli ATCC® 25922 was included for every test (Kehrenberg et al., 2007). Bacterial 
cultures were grown overnight on 5% Sheep blood agar plates (DMP) and incubated at 
37ºC. Bacterial culture was resuspended into 1000µl of 0.85% sterile saline (Appendix 
D) and adjusted to a cell concentration turbidity of ≈0.5 McFarland using Microscan 
Turbidity Meter (Dade Behring). Sterile Mueller-Hinton agar was prepared (Appendix D) 
and kept molten at 55ºC. The appropriate amount of antibiotic (nalidixic acid or 
ciprofloxacin) was added to the molten agar, gently swirled, two plates poured (110mm 
Petri dishes) and the process repeated with the addition of the EPI. Details of the 
concentrations and makeup of the antibiotics and EPI are provided in Appendix D. 
Bacterial suspensions (1000µl) were loaded into a 36 well plate spotter (MAST, 
Meyerside, United Kingdom) with 0.85% sterile saline serving as a negative control. The 
plates were spotted with equal amounts of all samples and incubated overnight at 37ºC. 
Results of inhibition of growth were recorded the following day. The MIC value was 
determined as the minimum concentration of antibiotic that was required to completely 
inhibit the growth of the bacterium. The involvement of an efflux pump with regard to 
quinolone resistance was indicated when an isolate showed a decreased MIC in the 








Figure 3.1. PFGE dendrogram of 19 nalidixic acid-resistant Salmonella Typhi isolates 
causing disease in South Africa, 2003 to 2007, showing similarity index, banding pattern, 
isolate number, MLVA type and MLVA profile. The two main PFGE clusters are 






Only nineteen of the twenty-seven Salmonella Typhi quinolone-resistant isolates were 
available for analysis. PFGE analysis differentiated the nineteen nalidixic acid-resistant 
isolates into five PFGE types (Table 3.1). However, MLVA was more discriminatory and 
differentiated the isolates into 10 MLVA types (Table 3.1). The superior discriminatory 
power of MLVA was illustrated within the PFGE type 2 cluster (14 isolates), which 
MLVA was able to divide into 6 MLVA types (Figure 3.1). MLVA type 16 was the most 
common type accounting for seven out of the fourteen isolates in the PFGE cluster 2. 
MLVA type 15, 16 and 17 only differ by a single allele (TR2) and may be considered 
under less strict circumstances as being identical. MLVA allows for a greater 
reproducibility and accuracy of result. 
 
The investigation into the involvement of an active efflux revealed a 16 or 32-fold 
decrease in nalidixic acid MIC and a 2 or 8-fold decrease in ciprofloxacin MIC in the 
presence of EPI. This suggests that an active efflux pump is a major contributory factor in 
the quinolone resistance of these Salmonella Typhi isolates (Table 3.1).
All qnr  screening results negative for Salmonella Typhi. 
Table 3.1. PFGE types, MLVA types and MIC results for all Salmonella Typhi isolates as well as the QRDR results for seven selected isolates.     





type3 MLVA profile (TR1-TR2-TR3)4 gyrA mutations parC mutations 
Nalidixic acid agar 
dilution MIC (µg/ml)5
Ciprofloxacin agar 
dilution MIC (µg/ml)5 Active Efflux 
TMI92173 2005 GA 1 23 234 443 566 X X 256 (8) 0.5 (0.0625) Yes 
TCD113560 2006 WC 1 19 228 435 566 Asp82-Gly; Ala119-Ser Tyr57-Ala;Ser80-Phe 512 (32) 0.5 (0.0625) Yes 
TTD1022834 2003 GA 2 25 214 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TTD1028222 2004 GA 2 15 207 475 566 X X 512 (32) 0.5 (0.0625) Yes 
TTD1025746 2004 KZN 2 17 207 379 566 X X 512 (32) 0.5 (0.0625) Yes 
TTD1025656 2004 WC 2 17 207 379 566 X X 512 (32) 0.5 (0.0625) Yes 
TCD83959 2005 EC 2 16 207 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TCD83947 2005 EC 2 18 261 000 542 X X 256 (8) 0.5 (0.0625) Yes 
TCD100247 2005 KZN 2 16 207 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TMi1648788 2005 KZN 2 24 241 427 566 X X 128 (8) 0.125 (0.0625) Yes 
TCD152229 2006 GA 2 16 207 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TCD107964 2006 WC 2 16 207 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TCD107432 2006 WC 2 16 207 000 566 Asp82-Gly; Ser83-Ala Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
TCD212418 2007 KZN 2 16 207 000 566 X X 512 (32) 0.5 (0.0625) Yes 
TCD185048 2007 WC 2 16 207 000 566 Ser83-Met; Asp87-Cys Tyr57-Gly; Ser80-Lys 512 (32) 0.5 (0.0625) Yes 
TCD235856 2007 GA 2 22 207 395 566 Ser83-Ala Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
TCD88972 2005 MP 3 18 261 000 542 Ala119-Gly Ser80-Ile >512 (32) 0.5 (0.0625) Yes 
TMI1647652 2005 WC 4 21 241 000 566 Gly81-Ser; Asp82-Gly Tyr57-Ser 256 (8) 0.125 (0.0625) Yes 
TCD200597 2007 KZN 5 18 261 000 542 Ser83-Phe Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
      
1: GA, Gauteng; WC, Western Cape; KZN, KwaZulu-Natal; EC, Eastern Cape; MP, Mpumalanga.       
2: PFGE types based on relatedness as based on a dendrogram cluster analysis of the patterns using the unweighted pair group method with arithmetic averages, with analysis of banding patterns incorporating the Dice-coefficient at an 
optimization setting of 0.5% and a position tolerance setting of 1.5%. PFGE types defined at ≥90% similarity. 
3: MLVA types based on MLVA profiles.        
4: 000 represents no amplification of the PCR product at locus TR2.      
5: Value in parenthesis represents the MIC with the addition 40 µg/ml β-Phe-Arg-naphthylamide  as an efflux pump inbihitor.    





The PFGE cluster 2 represented the majority of isolates which share a common ancestry. 
This immediately suggests that clonal spread of nalidixic acid resistance may have 
occurred. However QRDR sequencing data (discussed later) of selected isolates within 
this PFGE cluster 2 showed completely different QRDR mutation profiles (Table 3.1). 
This would suggest that quinolone-resistant isolates have emerged independently of one 
another, i.e. emergence of quinolone resistance in South African isolates of Salmonella 
Typhi is not clonally driven. 
 
An efflux pump as a mechanism of quinolone resistance has previously been observed in 
various Salmonella serotypes including Salmonella Typhi (Piddock et al., 2002; Gaind et 
al., 2006). Baucheron et al. (2002) illustrated the importance of the AcrB in 
fluoroquinolone resistance and TolC in multidrug resistant Salmonella Typhimurium 
(Baucheron et al., 2005). Although the AcrAB-TolC efflux system may vary between 
isolates (Kehrenberg et al., 2007) it has been shown that quinolone resistance is not as a 
result of one mechanism but due to a combination of mechanisms (Hopkins et al., 2005). 
A similar observation can be made for the South African isolates. Gyrase mutations alone 
do not account for quinolone resistance in Salmonella as it is believed that AcrAB pump 
is the primary mechanism for fluoroquinolone resistance, especially if the QRDR 
mutations do not sufficiently explain the resistant phenotype (Baucheron et al., 2002; 
Chu et al., 2005). For South African isolates, an active efflux is seen to be the major 
contributory mechanism to quinolone resistance; however it is not the only mechanism 
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because even in the presence of EPI, fifteen out of the nineteen isolates still show 
nalidixic acid resistance with MICs at 32μg/mℓ (Table 3.1). The role of qnr plasmids can 
be excluded as screening for the pentapeptide repeat genes qnrA, qnrB and qnrS did not 
identify the presence of these genes. This leaves mutations in the QRDR as the only other 
likely mechanism. 
 
Isolates TCD200597, TCD235856, TCD185048 and TCD107432 show mutations at gyrA 
positions Ser83 and/or Asp87, positions that have been previously described as important 
for quinolone resistance (Hopkins et al., 2005), therefore these mutations probably play a 
role in quinolone resistance in these isolates. At these positions, novel mutations (Ser83-
Met and Asp87-Cys) were observed in isolate TCD185048. Some of our isolates also 
show some novel mutations at novel positions in gyrA. Isolates 113560 and 88972 
showed a novel mutation at position 119 (Ala119-Ser) of gyrA. This above mutation was 
found in combination with a previously described mutation at position 82 (Asp82-Gly) 
(Ruiz, 2003).  Isolate 107432 also showed the Asp82-Gly mutation For isolates 113560, 
107432 and 88972, mutations at positions (Asp82 and Ala119) in gyrA may be operating 
as an alternative mechanism of resistance comparEd to the commonly reported mutation 
at positions Ser83 and Asp87. Levy, et al. (2004) provided evidence to suggest that 
selection pressure in terms of the antibiotics the bacteria is exposed to, is a determining 
factor in the resulting mutations in gyrA. Treatment strategies for salmonellosis differ for 
different regions and since quinolone-resistant Salmonella Typhi are not as commonly 
locally acquired in South Africa as comparEd to other Salmonella serotypes, the 
selection pressure may be driven by antimicrobial use in regions with elevated rates of 
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Salmonella Typhi infection. Single point source mutations at codons 83 and 87 of the 
gyrA have over the years received much attention as the cause of quinolone resistance, in 
particular nalidixic acid and as a result linked to decreased susceptibility of 
fluoroquinolones (Hirose et al., 2002; Saha et al., 2006). Mutations in gyrA are normally 
associated with nalidixic acid resistance and seen as the precursors to mutations in the 
topoisomerase IV proteins parC and parE resulting in fluoroquinolone resistance or 
decreased susceptibility (Baucheron et al., 2005). Conversely it has been strongly 
suggested that multiple mutations in gyrA are more important in conveying 
fluoroquinolone resistance than any respective combination of mutations in the gyrase 
and topoisomerase IV proteins. As important as mutations in gyrA are, these mutations 
themselves are not the defining contributory factor for quinolone resistance (Eaves et al., 
2002; Hopkins et al., 2005). Sequencing analysis of nalidixic acid-resistant Salmonella 
Typhi isolates showed no amino mutations in either gyrB or parE. The two regions are 
homologous with the latter being the secondary target for quinolones (Eaves et al., 2004). 
Mutations for both gyrB and parE remain rare for most Salmonella isolates as most 
researchers report mainly on findings of gyrA mutations (Hopkins et al., 2007). The role 
of gyrB and parE in quinolone resistance is unclear (Piddock et al., 2002), in particular 
gyrB, even in Salmonella isolates exhibiting high levels of fluoroquinolone resistance 
(Hopkins et al., 2007). The present study showed that all nalidixic acid-resistant isolates 
with amino mutations in gyrA also showed amino acid mutations in parC. Mutation at 
position Ser80 of parC was commonly present and involved the mutation of Ser80 to 
either Phe or Arg or Lys or Ile. Some novel parC mutations were also identified and 
these included Tyr57-Gly, Tyr57-Ala, Ser80-Lys and Ser80-Phe. ParC mutation at 
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positions Ser80 and Glu84 have previously been shown to be important for quinolone 
resistance (Hopkins et al., 2005). With regards to the parC mutation at position Tyr57, 
Baucheron et al. (2004) suggested that mutation at this position (Tyr57-Ser) is not likely 
to be involved in quinolone resistance. Results from the present study support this 
hypothesis. Mutations were found at Tyr57 for three of the isolates. For one of these 
(isolate 1647652), the mutation at position Ser80 of parC was notably absent while a 
Tyr57-Ser mutation was present. With efflux inhibited, this isolate was nalidixic acid-
susceptible (MIC, 8 µg/ml), which would support the view that a mutation at position 
Tyr57 of parC may be inconsequential, but the role of this mutation in combination with 
concurrent mutations cannot be overlooked. Overall, the role of parC mutations in 
quinolone-resistant Salmonella remains unclear. The above results suggest that mutation 
at position Ser80 of parC may be an important role player in quinolone resistance. The 
question remains concerning the role of mutations in both gyrA and parC. Sequencing 
data from our seven isolates showed mutations in both gyrA and parC. Based upon the 
results of previous studies (Chu et al., 2005; Hopkins et al., 2005) it was therefore 
expected that our test isolates should be resistant to the fluoroquinolone, ciprofloxacin. 
However, all seven isolates were susceptible (MICs, ≤0.5 µg/ml) to ciprofloxacin. Our 
results are therefore in more agreement with the results of Eaves et al. (2004) who found 
that isolates with mutations in both gyrA and parC were more susceptible to 
ciprofloxacin than isolates with mutations in gyrA alone. 
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Figure 4.1. PFGE dendrogram of 116 nalidixic acid-resistant Salmonella Enteritidis 
isolates causing invasive disease in South Africa, 2004 to 2006, showing similarity index, 
banding pattern and isolate number. The dendrogram shows 8 PFGE clusters with PFGE 












For the period 2004-2006, three-hundred and twenty-nine human isolates of Salmonella 
Enteritidis, were received by the EDRU, of which one-hundred and nineteen isolates 
were invasive, nalidixic acid-resistant. Only one-hundred and sixteen isolates were 
available for analysis. PFGE analysis resolved the invasive, nalidixic acid-resistant 
Salmonella Enteritidis isolates into thirty-six PFGE types and eight PFGE clusters at 
≥90% similarity (Figure 4.1). The largest PFGE cluster was the PFGE cluster 2 with 
eighty-nine isolates. The isolates constituting PFGE cluster 2 are a combination of 
isolates collected in the period 2004 to 2006 mostly from Gauteng. The distribution of the 
isolates across the dendrogram to result in one dominant PFGE cluster (89/116), suggests 
a common ancestry for this group of isolates.   
 
Thirty-seven randomly selected Salmonella Enteritidis isolates were screened to 
determine the contribution of an active efflux system to nalidixic acid resistance. The 
thirty-seven selected isolates all exhibited an 8 to 32-fold decrease in nalidixic acid MIC 
and a 2 or 8-fold decrease in ciprofloxacin MIC in the presence of the efflux pump 
inhibitor (Table 4.1). 
 
 














































Isolate Year Province1 PFGE 
type2







TCD117250 2006 GA 2 Ser83-Ala Tyr57-Arg >512(32) 1(0.5) Yes 
TCD123778 2006 GA 2 Ser83-Phe Ser80-Arg >512(32) 0.5(0.0625) Yes 
TCD175828 2006 GA 2 Ser83-Ala Tyr57-Arg >512(32) 0.5(0.0625) Yes 
TCD170833 2006 GA 2 Ser83-Ala Tyr57-Arg >512(32) 1(0.5) Yes 
TDC171403 2006 GA 2 Ser83-Phe Tyr57-Ala >512(32) 0.5(0.25) Yes 
TCD175830 2006 GA 2 Ser83-Ala Tyr57-Arg >512(32) 0.5(0.25) Yes 
TCD116579 2006 GA 2 Ser83-Ala Tyr57-Gly; Ser80-Lys >512(32) 0.5(0.25) Yes 
TCD113901 2006 GA 2 Ser83-Phe Tyr57-Ser >512(32) 0.5(0.0625) Yes 
TCD136018 2006 GA 2 Ser83-Ala Tyr57-Phe; Ser80-Pro >512(32) 0.5(0.25) Yes 
TCD139370 2006 GA 2 Ser83-Ala Tyr57-Ala >512(32) 0.5(0.0625) Yes 
TDC129513 2006 GA 2 Ser83-Phe Tyr57-Arg >512(32) 0.5(0.25) Yes 
TCD139740 2006 GA 2 Ser83-Ala Tyr57-Ala >512(32) 0.5(0.25) Yes 
TCD174124 2006 GA 2 Ser83-Ala Ser80-Phe >512(32) 0.5(0.0625) Yes 
TCD139743 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD121346 2006 GA 2 X X >512(32) 0.5(0.0625) Yes 
TCD137712 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD138119 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD119210 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD129777 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD141816 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD137312 2006 MP 2 X X >512(32) 0.5(0.25) Yes 
TCD115452 2006 MP 2 X X >512(32) 0.5(0.25) Yes 
TCD152454 2006 NW 2 X X >512(32) 0.5(0.25) Yes 
TCD110407 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD134118 2006 GA 2 X X >512(32) 0.5(0.25) Yes 
TCD127495 2006 NW 2 X X >512(32) 0.5(0.25) Yes 
TCD140224 2006 WC 2 X X >512(32) 0.5(0.25) Yes 
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Table 4.1. Continued PFGE types,  MIC results and QRDR results for randomly selected Salmonella Enteritidis isolates. 
 
 
 Isolate Year Province1 PFGE 
type2







TCD114782 2006 GA 3 X X >512(32) 0.5(0.25) Yes 
TCD119691 2006 GA 3 X X >512(32) 0.5(0.25) Yes 
TCD115458 2006 GA 3 X X >512(32) 0.5(0.25) Yes 
TCD117505 2006 GA 5 X X >512(32) 0.5(0.25) Yes 
TCD116582 2006 GA 5 X X 512(32) 0.5(0.25) Yes 
TCD135215 2006 KZN 6 X X 128(16) 0.5(0.25) Yes 
TTD1029487 2004 WC O Ser83-Ala Tyr57-Arg >512(16) 0.5(0.25) Yes 
TTD1029689 2004 GA O Ser83-Ala Ser80-Lys >512(16) 0.5(0.25) Yes 
TMI1648844 2005 GA O Ser83-Phe Tyr57-Ser >512(64) 0.5(0.25) Yes 















1: GA, Gauteng; WC, Western Cape; KZN, KwaZulu-Natal; EC, Eastern Cape; MP, Mpumalanga; NW, North West. 
2: PFGE types based on relatedness as based on a dendrogram cluster analysis of the patterns using the unweighted pair group method with arithmetic averages, with analysis of banding 
patterns incorporating the Dice-coefficient at an optimization setting of 0.5% and a position tolerance setting of 1.5%. PFGE types defined at ≥90% similarity. PFGE type O, are isolates outliers 
that did not fit into a PFGE  cluster at ≥90% similarity. 
3: Value in parenthesis represents the MIC with the addition 40 µg/ml β-Phe-Arg-naphthylamide as an efflux pump inbihitor.  
   *: X represents not analysed. 





The possible shared common ancestry for the Salmonella Enteritidis isolates suggests that 
a clonal spread of nalidixic acid resistance may have occurred. This thought may be 
refuted when one considers the number of PFGE types resulting from the dendrogram 
(Figure 4.1). Thirty-six PFGE types suggest that there is a fair amount of variability 
amongst the isolates which in turn implies that quinolone resistance with regard to these 
Salmonella Enteritidis isolates was not clonally spread.  Analysis of the QRDR mutations 
provides further clarity (discussed later). 
 
As with the Salmonella Typhi isolates, the results of the phenotypic investigation 
suggests that an active efflux system seems to be the major contributory factor toward the 
quinolone resistance of these invasive Salmonella Enteritidis isolates. This result is in 
partial agreement with the findings of Braoudaki and Hilton (2004) who have previously 
shown that the over-expression of an active efflux pump in Salmonella Enteritidis isolates 
is an adaptive mechanism of resistance in response to antimicrobial agents. 
 
Although an active efflux pump is thought to be the major contributory mechanism to 
quinolone resistance, it cannot be seen as the sole contributory mechanism. In the 
presence of an efflux pump inhibitor thirty-four out of the thirty-seven screened isolates 
still showed nalidixic acid resistance with an MIC of 32µg/ml (Table 4.1). All thirty-
seven Salmonella Enteritidis isolates also showed no positive results for the qnr plasmid 
screening, thus excluding qnr plasmids as a contributory mechanism of resistance. 
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Mutations in the QRDR remain the only explanation for the high level of quinolone 
resistance observed in these Salmonella Enteritidis isolates.   
 
Seventeen isolates selected for sequencing showed mutations in gyrA at positions Ser83 
(Table 4.1). Mutations in gyrA position Ser83 have previously been shown to be an 
important contributor to quinolone resistance (Bertrand et al., 2006). The commonality of 
the gyrA mutations at position Ser83 for all seventeen isolates [including 13 isolates from 
PFGE cluster 2 and four outliers (Table 4.1)] provides further evidence to the earlier 
suggestion, based on PFGE analysis, that these Salmonella Enteritidis isolates may have a 
common ancestry. This finding is in correlation with the suggestion that the distribution 
of gyrA mutations depend on the source of the isolates, but maybe more likely to the 
exposure of similar selection pressures, that is, antimicrobials (Lindstedt et al, 2004). As 
antimicrobial treatment strategies are similar for most regions quinolone resistance for 
these Salmonella Enteritidis may have occurred independently as suggested by the 
numerous PFGE types. 
 
Sequencing analysis of the gyrB and parE regions of the seventeen selected Salmonella 
Enteritidis isolates revealed no amino acid mutations in either gyrB or parE. In contrast 
to those findings, sequencing analysis of the gyrA homologous region, parC of the same 
isolates showed mutations in parC at positions Tyr57 and Ser80. Two isolates, 
TCD113901 and TMI1648844 showed amino acid changes of Tyr57-Ser which has 
previously been described (Hopkins et al., 2005). Four novel amino mutations at Tyr57 
were shown in twelve of the isolates, with the changes being Tyr57-Arg, Tyr57-Ala, 
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Tyr57-Gly or Tyr57-Phe (Table 4.1). Three novel mutations were also observed at Ser80, 
with the changes being Ser80-Phe, Ser80-Pro or Ser80-Lys (Table 4.1). One isolate, 
TCD123778, exhibited a previously described parC mutation of Ser80-Arg (Hopkins et 
al., 2005). Three isolates, TCD84518, TCD116579 and TCD136018, showed a 
combination of mutations at both positions 57 and 80 of parC, as well as at position 83 of 
gyrA (Table 4.1). It would be expected that these three isolates along with the other 
fourteen sequenced isolates would be fluoroquinolone-resistant as a result of the multiple 
mutations, but the isolates are fully susceptible to the fluoroquinolone ciprofloxacin 
(Table 4.1). This finding is in accordance with results of Eaves et al. (2004) who 
suggested that isolates with mutations in both gyrA and parC were more susceptible to 
ciprofloxacin than isolates with mutations in gyrA alone.  The contribution of mutations 
at position Tyr57 of parC has come under criticism with Baucheron et al. (2004) 
suggesting that this mutation plays no role in quinolone resistance. For our study the MIC 
results in the presence of an efflux pump inhibitor showed that for thirteen out the 
seventeen sequenced isolates, that possessed a mutation at Tyr57 had a nalidixic acid 
MIC of ≥32µg/ml (Table 4.1). The above finding would suggest that a mutation at 
position Tyr57 of parC may play a role in quinolone resistance, thus contradicting the 
suggestion of Baucheron et al. (2004). However, mutations at Tyr57 of parC were found 
in combination with mutations at position Ser83 of gyrA which are associated with 
quinolone resistance (Cloeckaert & Chaslus-Dancla, 2001). The role of mutations at 
























































































































Figure 5.1. PFGE dendrogram of 137 nalidixic acid-resistant Salmonella Isangi isolates 
causing invasive disease in South Africa, 2004 to 2006, showing similarity index, 
banding pattern and isolate number. The dendrogram shows 19 PFGE clusters with PFGE 

















For the period 2004-2006, one-thousand and five human isolates of Salmonella Isangi, of 
which, one-hundred and forty-three were invasive, nalidixic acid-resistant. Molecular 
analysis was conducted on one-hundred and thirty-seven available isolates. Analysis of 
the PFGE patterns of the nalidixic acid-resistant Salmonella Isangi isolates causing 
invasive disease, for the period 2004-2006, resulted in a dendrogram resolved to fifty-
seven PFGE types (As defined in chapter 2) (Figure 5.2). The dendrogram constituted 
nineteen PFGE type clusters. PFGE cluster 8 was the largest cluster with fifteen isolates 
and the other eighteen PFGE clusters numbered between two to eleven isolates. 
 
Thirty-two randomly selected isolates were screened for the involvement of an active 
efflux system as a possible mechanism of quinolone resistance. All thirty-two isolates 
exhibited the presence of an active efflux system (Table 5.2).
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Isolate Year Province1 PFGE 
type2







TTD1024955 2004 GA 3 Gly81-Lys; Asp87-Ile Tyr57-Ser >512(16) 0.125(0.0625) Yes 







>512(32) 0.125(0.0625) Yes 






>512(32) 0.125(0.0625) Yes 
TCD168014 2006 MP 4 X X >512(32) 0.125(0.0625) Yes 




Gly78-Phe; Ser80-Pro  
 
>512(32) 0.125(0.0625) Yes 
TCD121353 2006 WC 5 X X >512(32) 0.0625(<0.0625) Yes 




>512(8) 0.125(0.0625) Yes 




>512(32) 0.5(0.0625) Yes 
TCD104960 2005 EC 7 Gly81-Lys; Asp87-Ile Tyr57-Ser >512(32) 0.125(0.0625) Yes 




>512(32) 0.125(0.0625) Yes 
TCD142070 2006 KZN 8 X X >512(32) 0.125(0.0625) Yes 
TCD135180 2006 KZN 8 X X >512(32) 0.5(0.0625) Yes 
TCD139881 2006 KZN 10 Ser83-His; Asp87-Cys; 
Leu98-His; Ala119-Phe 
Tyr57-Arg >512(32) 0.125(0.0625) Yes 
TCD132205 2006 KZN 10 X X >512(32) 0.5(0.0625) Yes 
TCD115424 2006 KZN 10 X X >512(32) 0.125(0.0625) Yes 





>512(32) 0.125(0.0625) Yes 
TCD122195 2006 GA 12 X X >512(32) 0.25(0.0625) Yes 
TCD144912 2006 KZN 13 X X >512(32) 0.125(0.0625) Yes 
TCD107441 2006 WC 14 X X >512(32) 0.125(0.0625) Yes 
TCD150654 2006 KZN 16 Asp82-Pro;Ser83-His; 
Asp87-Cys; Leu98-His 
Tyr57-Ser; Ser80-Pro >512(32) 0.125(0.0625) Yes 
TCD147366 2006 KZN 0.125(0.0625) >512(32) X X 16 Yes 
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1: GA, Gauteng; WC, Western Cape; KZN, KwaZulu-Natal; EC, Eastern Cape; MP, Mpumalanga.  
2: PFGE types based on relatedness as based on a dendrogram cluster analysis of the patterns using the unweighted pair group method with arithmetic averages, with analysis of banding 
patterns incorporating the Dice-coefficient at an optimization setting of 0.5% and a position tolerance setting of 1.5%. PFGE types defined at ≥90% similarity. PFGE type O, are isolates 
outliers that did not fit into a PFGE  cluster at ≥90% similarity. 
3: Value in parenthesis represents the MIC with the addition 40 µg/ml β-Phe-Arg-naphthylamide as an efflux pump inbihitor. 
 *: X represents not analysed. 
All qnr  screening results negative for Salmonella Isangi. 
 
                                                                                                                                                                                                                                                
 
 
Isolate Year Province1 PFGE 
type2







TCD152844 2006 KZN 17 Gly81-Lys; Asp87-Ile; 
Ala119-Phe 
Tyr57-Ser >512(32) 0.125(0.0625) Yes 
TCD150664 2006 KZN 17 X X >512(32) 0.125(0.0625) Yes 
TCD105825 2006 GA 
O Asp82-His;Ser83-His; 









































TCD155842 2006 KZN O X X >512(32) 0.125(0.0625) Yes 
TCD152864 2006 KZN O X X >512(32) 0.125(0.0625) Yes 
TCD150898 2006 WC O X X >512(64) 0.125(0.0625) Yes 
TCD114240 2006 0.25(0.0625) X >512(32) X O WC Yes 
5.2. Discussion 
 
Although PFGE cluster 8 constitutes the largest cluster, the majority of the isolates were 
distributed across many small clusters. The large number of PFGE types and clusters 
suggests that these South African Salmonella Isangi isolates evolved from different 
sources. The possible variability of sources of Salmonella Isangi implies that nalidixic 
acid resistance in South African Salmonella Isangi evolved independently i.e. is not 
clonally driven. 
 
This result illustrates that Salmonella Isangi also exhibits an active efflux under stress 
which is in accordance with findings for other different Salmonella serotypes (Piddock et 
al., 2002; Gaind et al. 2006). The effect of the efflux pump can be illustrated by focusing 
on three isolates, TTD1024955, TCD97401 and TCD105825. These three isolates all 
exhibit a high level of nalidixic acid resistance (MIC ≥512 µg/ml). The inhibition of the 
efflux pump in these three isolates decreases their respective nalidixic acid MIC values to 
within the susceptible range (MIC ≤16µg/ml). This result shows that for these three 
isolates the efflux pump is the main contributory mechanism of quinolone resistance. 
Although all three of these isolates exhibit mutations in both gyrA and parC regions of 
the QRDR, the fact that their nalidixic acid MIC values were decreased to a value that is 
within the susceptible range suggests that the mutations in both the gyrA and parC 
regions of these three isolates may not play a role in the development of clinical 
quinolone resistance. These results may be due to the over-expression of the AcrAB-
TolC efflux system (Olliver et al., 2005).  The remaining twenty-nine isolates although 
 51
susceptible to ciprofloxacin still exhibit some resistance to nalidixic acid in the presence 
of an efflux pump inhibitor, suggesting that for these twenty-nine isolates a secondary 
mechanism is a contributing factor to quinolone resistance.  
 
Sequencing of gyrB and parC revealed no mutations, therefore the role of gyrB and parE 
mutations can be excluded as they remain rare as previously suggested (Hopkins et al., 
2007). Screening for the pentapeptide repeat genes qnrA, qnrB and qnrS showed no 
positive results thus eliminating the qnr plasmids as a contributory mechanism of 
resistance. The seventeen isolates selected for sequencing all exhibited mutations in gyrA 
and parC. With the exception of the three aforementioned isolates, it would seem as 
though the gyrA and parC mutations in the remaining fourteen isolates contribute to 
quinolone resistance. All the sequenced isolates exhibited a combination of mutations at 
gyrA. The previously published Gly81-Asp as well as novel mutations Gly81-Lys, 
Asp82-His/Pro, Ser83-His/Pro, Asp87-Cys/Ile/Ala, Leu98-His/Pro/Met and Ala119-Phe 
were identified. Seven isolates exhibited a mutation at gyrA position Gly81. Another 
common site for mutation was at gyrA position Asp82 (Table 5.2). All seventeen isolates 
showed mutations in a combination of positions Gly81, Asp82, Ser83, Asp87 and Leu98. 
These mutations were found in combination involving either all five positions or three of 
the four positions within the gyrA (Table 5.2). The various combinations of mutations in 
the gyrA would imply that all these sequenced isolates should be fluoroquinolone-
resistant (Eaves et al., 2004) but they are not (Table 5.2).  
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This result is in accordance with Eaves et al. (2004) who found that isolates exhibiting 
mutations in both gyrA and parC are more susceptible to fluoroquinolones. All seventeen 
sequenced Salmonella Isangi isolates exhibited mutations at parC position Tyr57, with 
some isolates showing multiple mutations in the parC region (Table 5.2). As previously 
suggested the role of the Tyr57 mutation in its contribution to quinolone resistance is 
questionable (Baucheron et al., 2004). Isolate TCD105825 showed a double mutation in 
parC in positions Tyr57 and Ser80 but with the inhibition of the efflux pump the isolates 
nalidixic acid MIC value was within the susceptible range (Table 5.2). In contradiction 
isolate TCD150654 with a double mutation at positions Tyr57 and Ser80 of parC with 
the inhibition of the efflux pump was still nalidixic acid resistant. The role of parC 
mutations in quinolone resistance in Salmonella is poorly understood (Hopkins et al., 
2005), thus it is difficult to conclude that the parC mutations found in these South 
African Salmonella Isangi isolates play a role in quinolone resistance. The main 
contributory mechanisms for quinolone resistance in these South African Salmonella 
Isangi isolates is a combination of an active efflux pump, gyrA mutations and possibly 
parC mutations. However there is insufficient evidence from this study to suggest that 
additional mutations in gyrA and/or in parC do not extend quinolone resistance to 
fluoroquinolone resistance. We cannot say that any single unique combination of 
mutations is the defining factor for quinolone resistance, as there seems to be multiple 
mutations and multiple combinations of mutations in positions 81 to 119 of gyrA and 57 



















































































































































































































Figure 6.1. PFGE dendrogram of nalidixic acid-resistant Salmonella Typhimurium 
isolates causing invasive disease in South Africa, 2004 to 2006, showing similarity index, 
banding pattern and isolate number. The dendrogram shows 38 PFGE clusters with PFGE 





















 Figure 6.2. MLVA dendrogram of 27 nalidixic acid-resistant Salmonella Typhimurium 
isolates from PFGE cluster 9 causing invasive disease in South Africa, 2004 to 2006, 
showing similarity index, VNTR loci (STTR9, 5, 6, 10-pl and 3), isolate number and 
MLVA type.  
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Two-thousand six-hundred and twenty-four human isolates of Salmonella Typhimurium 
were received by the EDRU for the period 2004-2006, of which, six-hundred and twenty-
four were invasive, nalidixic acid-resistant. Molecular analysis was conducted on five-
hundred and sixteen available isolates. PFGE analysis resolved the invasive, nalidixic 
acid-resistant Salmonella Typhimurium isolates into ninety-five PFGE types (As defined 
in chapter 2) (Figure 6.1). The isolates were distributed across thirty-eight PFGE clusters, 
with two large clusters dominating the dendrogram. PFGE cluster 9 constituted by two-
hundred and nine isolates and PFGE cluster 13 constituted by eighty-three isolates 
(Figure 6.1). Although the dendrogram is dominated by two large cluster, the number 
immense number of PFGE types and PFGE clusters constituting the dendrogram suggests 
that nalidixic-acid resistance amongst the South African Salmonella Typhimurium 
isolates is not clonally driven. 
 
Forty-six randomly selected isolates were analysed using MLVA specific for Salmonella 
Typhimurium as a method of evaluating the PFGE results. MLVA was able to group 
isolates from different PFGE types as either different or similar based on the isolates 
allelic profile (Table 6.1).  Twenty seven isolates from the PFGE cluster 9 were analysed. 
PFGE grouped all twenty seven isolates as similar but MLVA distinguished the same 
twenty seven isolates into five MLVA types (Table 6.1). The dendrogram for the twenty-
seven PFGE cluster 9 isolates created from the MLVA analysis (Figure 6.2) illustrates the 
highly discriminatory nature of the analysis as the isolates were selected from different 
PFGE type clusters. MLVA was able to group PFGE unrelated isolates as either the same 
MLVA type or as a closely related MLVA type. In contradiction, a number of isolates 
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belonging to MLVA type 9 were separated into ten different PFGE types (Table 6.1). In 
this case PFGE can be said to be more discriminatory than MLVA although MLVA can 
discriminate between isolates with identical PFGE patterns. 
 
The investigation into the possible contributory mechanisms of quinolone resistance for 
the Salmonella Typhimurium isolates showed that out of forty-one randomly selected 
isolates forty isolates exhibited an over-over-active efflux pump (Table 6.1). Isolates 
TCD110365, TTD1027026 and TTD1025442 were found to have been harbouring the 
qnrB plasmid.  
 












Nalidixic acid agar 
dilution MIC (µg/ml)5
Ciprofloxacin agar 
dilution MIC (µg/ml)5 Active Efflux 









TMI1649855 2005 GA 9 X X Asp87-Gly Tyr57-Arg X >512(32) 0.125(0.0625) Yes 
TCD101416 2005 GA 9 X X Asp87-Gly Tyr57-Arg X >512(32) 0.125(0.0625) Yes 
TCD102423 2005 GA 9 X X Asp87-Gly Tyr57-Arg X >512(64) 0.125(0.0625) Yes 
TCD117150 2006 GA 9 B 160-248-342-355-405 X X X X X X 
TCD122153 2006 GA 9 B 160-248-342-355-405 X X X X X X 
TCD128043 2006 GA 9 B 160-248-342-355-405 X X X X X X 
TCD119596 2006 GA 9 A 160-248-328-355-405 X X X X X X 
TCD109669 2006 GA 9 D 160-264-342-355-405 X X X X X X 
TCD115462 2006 GA 9 F 160-264-328-355-405 X X X X x x 
TCD134296 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD117039 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD147857 2006 GA 9 D 160-264-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD150223 2006 GA 9 F 160-264-328-355-405 X x X X X X 
TCD114158 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD128717 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD113900 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD117503 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD107373 2006 GA 9 A 160-248-328-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TCD121282 2006 GA 9 B 160-248-342-355-405 Asp87-Gly Tyr57-Arg X 256(32) 0.25(0.125) Yes 
TDC110365 2006 GA 9 D 160-264-342-355-405 Wild Type Wild Type qnrB 32(32) 0.25(0.25) No 
TCD106543 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.5(0.125) Yes 
TCD105829 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.5(0.125) Yes 
TCD132216 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD118076 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.5(0.125) Yes 
TCD132144 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD109959 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD106529 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.5(0.125) Yes 
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(µg/ml)5 Active Efflux 
TCD137661 2006 GA 9 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD111598 2006 GA 9 D 160-264-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD116003 2006 GA 9 E 160-248-342-355-390 X X X X X X 
TCD147245 2006 GA 13 B 160-248-342-355-405 X X X X X X 
TCD167861 2006 GA 15 B 160-248-342-355-405 X X X X X X 
TCD152829 2006 GA 18 B 160-248-342-355-405 X X X X X X 
TCD145683 2006 GA 18 B 160-248-342-355-405 X X X X X X 
TCD146221 2006 GA 18 F 160-264-328-355-405 Asp87-Tyr Tyr57-Gly X 256(32) 0.25(0.125) Yes 
TCD145688 2006 GA 18 B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD145686 2006 GA 19 X X Asp87-Tyr Tyr57-Gly X 256(32) 0.25(0.125) Yes 
TCD155725 2006 GA 19 B 160-248-342-355-405 Asp87-Tyr Tyr57-Gly X 256(32) 0.25(0.0625) Yes 
TCD144800 2006 GA 19 A 160-248-328-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD145418 2006 GA 20 B 160-248-342-355-405 Asp87-Tyr Tyr57-Gly X 256(32) 0.25(0.0625) Yes 
TCD111617 2006 GA 22 B 160-248-342-355-405 Asp87-Tyr Tyr57-Gly X 256(32) 0.25(0.125) Yes 
TTD1027026 2004 GA 27 X X Asp87-Lys Tyr57-Ser qnrB >512(32) 4(2) Yes 
TTD1025442 2004 GA 27 X X Asp87-Lys Tyr57-Ser qnrB >512(32) 4(2) Yes 
TCD106282 2006 GA 28 C 160-216-342-370-450 Asp87-Lys Tyr57-Ser X 256(32) 0.25(0.125) Yes 
TCD150224 2006 GA 31 C 160-216-342-370-450 X X X 256(32) 0.25(0.125) Yes 
TCD156534 2006 GA 31 A 160-248-328-355-405 Asp87-Lys Tyr57-Ser X 256(32) 0.25(0.125) Yes 
TCD111634 2006 GA 32 B 160-248-342-355-405 X X X X X X 
TCD177146 2006 GA 32 G 160-264-314-355-405 X X X X X X 
TCD175811 2006 GA 32 G 160-264-314-355-405 Asp87-Lys Tyr57-Ser X 256(32) 0.25(0.0625) Yes 
TTD1026858 2004 KZN O 








TMI1648592 2005 GA O X X Ser83-Phe Ser80-Arg X >512(32) 0.25(0.125) Yes 
TDC119684 2006 GA O A 160-248-328-355-405 X X X 256(32) 0.25(0.125) Yes 
TCD113899 2006 GA O B 160-248-342-355-405 X X X 256(32) 0.25(0.0625) Yes 
TCD118196 2006 GA O B 160-248-342-355-405 X X X 256(32) 0.25(0.125) Yes 
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1: GA, Gauteng; KZN, KwaZulu-Natal  
2: PFGE types based on relatedness as based on a dendrogram cluster analysis of the patterns using the unweighted pair group method with arithmetic averages, with analysis of banding 
    patterns incorporating the Dice-coefficient at an optimization setting of 0.5% and a position tolerance setting of 1.5%. PFGE types defined at ≥90% similarity. PFGE type O, are isolates 
    outliers that did not fit into a PFGE  cluster at ≥90% similarity. 
3: MLVA types based on MLVA profiles.   
4: MLVA profiles in an allelic string of STTR9-STTR5-STTR6-STTR10pl-STTR3 
5: Value in parenthesis represents the MIC with the addition 40 µg/ml β-Phe-Arg-naphthylamide  as an efflux pump inbihitor. 







 Lindstedt et al. (2003) suggested that PFGE always was not sensitive enough to 
distinguish amongst strains portraying certain phenotypic characteristics such as 
antibiotic resistance, as the strains all possessed identical PFGE patterns: thus the 
development of MLVA. Many further studies have bettered the technique and the 
upgrade to a more automated MLVA has enhanced the discriminatory power of the 
technique (Lindstedt et al., 2004). The repeatability and consistency of results have made 
sharing of MLVA data easier for international and outbreak purposes (Lindstedt et al., 
2007; Torpdahl et al., 2007). The use of PFGE as the typing method of Salmonella in 
general is still seen as the “gold standard” and its results still acceptable, especially for 
routine surveillance (Lindstedt, 2005; Torpdahl et al., 2006).  
 
In the presence of EPI, a four-fold decrease in MIC was observed for both nalidixic acid 
and ciprofloxacin for all forty-one isolates (Table 6.1) indicating that an efflux pump is 
playing a role in quinolone resistance. However an efflux pump was not the only 
contributing mechanism of resistance as the MIC for nalidixic acid for all forty-one of the 
isolates in the presence of an efflux pump inhibitor was as low as 32µg/ml (Table 6.1). 
Baucheron et al. (2004) previously showed that Salmonella Typhimurium show signs of 
an over-over-active efflux pump in response to antibiotics.  
 
In our current study, isolate TCD110365 was the exception to the above. This isolate was 
PCR positive for the qnrB (Table 6.1). The PCR positive qnrB result was confirmed by 
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nucleotide sequence analysis of the gene. QRDR sequences for this isolate showed no 
mutations in any of the genes (Wild Type; Table 6.1), so mutation in the QRDR was 
excluded as a mechanism for quinolone resistance. Agar dilution MIC’s for nalidixic acid 
and ciprofloxacin showed no involvement in resistance of an over-active efflux pump, as 
there was no difference in MIC values following testing in the absence or presence of an 
efflux pump inhibitor. The agar dilution MIC’s did illustrate the isolates low-level of 
nalidixic acid resistance (MIC, 32µg/ml) and susceptibility to ciprofloxacin (MIC, 
0.25µg/ml) (Table 6.1). The low-level nalidixic acid resistance of this Salmonella 
Typhimurium can be attributed to the presence of the qnrB. In addition, the ciprofloxacin 
MIC of 0.25µg/ml is seen by many as an increased MIC and the isolate may be described 
as having a reduced susceptibility to ciprofloxacin (Hopkins, et al., 2008). Isolates such 
as these, that confer low-level quinolone resistance due to qnr genes, facilitate the 
selection higher-level resistance mutants. This is the first report of qnr plasmid mediated 
quinolone resistance in South African Enterobacteriaceae.  
 
Two other isolates, TTD1027026 and TTD1025442 were also positive for the qnrB. 
These two isolates were also found to have an over-active efflux pump that was 
contributory to the development of quinolone resistance and mutations in the gyrA 
(Asp87-Lys) and parC (Tyr57-Ser) of the QRDR (Table 6.1). The combination of all 
these mechanisms contributed to both isolates being not only nalidixic acid-resistant 
(MIC, ≥512µg/ml), but also ciprofloxacin-resistant (MIC, ≥4µg/ml) (Table 6.1). The 
inhibition of the efflux pump resulted in the decrease of both nalidixic acid and 
ciprofloxacin MIC’s but the isolates were still nalidixic acid-resistant and exhibited 
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intermediate resistance to ciprofloxacin (Table 6.1).  The combination of the mutations in 
both the gyrA and parC regions, as well as the presence of the qnrB was sufficient to 
result in these isolates being nalidixic acid-resistant and intermediately resistant to 
ciprofloxacin.  
 
The role of the qnrB in these two isolates is illustrated when looking at the gyrA and 
parC mutations. Both TTD1027026 and TTD1025442 exhibit gyrA mutation Asp87-Lys 
and parC mutation Tyr57-Ser. These mutations are also found in ciprofloxacin 
susceptible isolates TCD106282 and TCD156534 (Table 6.1). These mutations can be 
excluded as the contributory mechanism for ciprofloxacin resistance in isolates 
TTD1027026 and TTD1025442. The qnrB in TTD1027026 and TTD1025442 plays a 
different role to the one it did with regard to TCD110365, as in these two isolates it is the 
defining factor in fluoroquinolone resistance. The combination of the various 
mechanisms have been previously been touted as the factors required for fluoroquinolone 
resistance as opposed to the contribution of just a single mechanism (Hopkins, et al., 
2007). 
 
For all these sequenced South African quinolone-resistant Salmonella Typhimurium 
isolates, the mutations in the gyrA and parC regions of the QRDR are fairly uniform 
(Table 6.1). All sequenced PFGE type 9 isolates with the exception of TTD1026502, 
displayed mutations at gyrA Asp87-Gly and a novel parC mutation Tyr57-Arg. All the 
isolates with the exception of TTD1026502 were susceptible to ciprofloxacin although it 
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has been previously suggested that isolates with mutations in both gyrA and parC exhibit 
a fluoroquinolone resistance (Baucheron et al., 2005).  
 
The mutation Asp87-Gly has previously shown to be a contributing factor to quinolone 
resistance (Hirose et al., 2002) but the novel mutation at parC Tyr57-Arg may not play a 
role as Baucheron et al. (2004) suggested that mutation at Tyr57 are not important in 
conferring resistance to fluoroquinolones. This would also provide evidence for the 
suggestion of Eaves et al. (2004), that isolates with mutations in both the gyrA and parC 
are more susceptible to fluoroquinolones. This implies that the main contributory 
mechanism of resistance for the isolates from PFGE cluster 9 is a combination of an 
over-active efflux pump and mutation(s) in gyrA. The same can be said for the other 
sequenced isolates from different PFGE types or clusters. The commonality amongst the 
isolates is mutations in gyrA Asp87 and parC Tyr57 (Table 6.1). Although the amino acid 
changes differ, the argument remains the same. The role of the parC mutation remains 
unclear as it may not play a role in quinolone-resistant Salmonella as these mutations are 
not found without a gyrA mutation (Eaves et al., 2004) and may also be dependant on an 
over-active efflux system. Ling et al (2003) showed that the mutation at Tyr57 
contributed to an increase in ciprofloxacin in their Salmonella but they did not investigate 
the role of an over-active efflux system. 
 
Isolate TTD1026502 from PFGE type 9 cluster and two outlying isolates TTD1026858 
and TMI1648592 possessed different combinations of gyrA and parC mutations, as 
comparEd to those discussed above. Using agar dilution MIC testing, both TTD1026858 
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and TTD1026502 were found to be ciprofloxacin resistant (MIC, 16µg/ml). This isolate 
showed gyrA mutations at Ser83-Phe and Asp87-Gly and parC mutation Ser80-Arg. The 
combination of these mutations with the inhibition of the efflux pump, which was only 
evident with change in ciprofloxacin MIC, still resulted in the isolates being 
ciprofloxacin resistant (MIC, 4µg/ml) (Table 6.1). All the mutations displayed by 
TTD1026858 and TTD1026502 have been previously shown to influence quinolone 
resistance (Hopkins et al., 2005) and with combination of the over-active efflux pump the 
isolate is highly-resistant to ciprofloxacin (MIC, 16µg/ml).  TMI1648592 possessed 
mutations at gyrA Ser83-Phe and parC Ser80-Arg but was only resistant to nalidixic acid. 
The mutation Ser83 in gyrA was shown to influence quinolone resistance (Ling et al., 
2003) but in combination with the parC mutation Ser80-Arg (which was found in 
TTD1026858 and TTD1026502) one would expect TMI1648592 to be ciprofloxacin 
resistant but it is not (Table 6.1). The difference between TMI1648592 and, TTD1026858 
and TTD1026502 is that, TTD1026858 and TTD1026502 posses a second gyrA mutation 
at Asp87-Gly. Eaves et al. suggested that an isolate requires multiple mutations in the 
gyrA to acquire fluoroquinolone resistance rather than a mutation in the topoisomerase 
region. Thus the second mutation at Asp87-Gly is an important role player in 
fluoroquinolone resistance.  
 
The probable contributory mechanisms for quinolone resistance in these South African 
Salmonella Typhimurium isolates are a combination of an over-active efflux pump, gyrA 
mutation and possibly parC mutation. Low level quinolone resistance may also be 
conferred via plasmid mediated resistance namely the qnrB plasmid. It is apparent that a 
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combination of mechanisms may be necessary for high-level fluoroquinolone resistance. 
This could be in the form of (1) qnr, efflux pump, gyrA mutation and possibly parC 
mutation, or (2) efflux pump, double gyrA mutation and possibly parC mutation. The 
evidence presented by this study does not allow for any confident conclusions to be 
drawn as to what mechanisms play a role in quinolone resistance but only for further 





Chapter 7: General Discussion and Conclusion 
 
This study was the first attempt to describe the molecular epidemiology and mechanism 
of resistance of invasive quinolone-resistant South African isolates of any of the four 
Salmonella serotypes subjected to this study. More especially involving the analysis of 
the large number of isolates collected over a three year period for the NTS serotypes and 
five year period for the Salmonella Typhi. The majority of the isolates analyzed in this 
study were collected from the Gauteng area resulting in a biased sample, but the EDRU is 
dependant on isolates received from hospitals participating in routine surveillance. The 
large number of isolates available for Gauteng may be due to under reporting of 
salmonellosis in other provinces or poor infrastructure and the unavailability of resources 
in those provinces for the effective processing of patient samples or that the EDRU is 
located in Gauteng, an academic center, and for that reason isolates from Gauteng are 
easily obtained and reported. This phenomenon is noted by the EDRU and they are 
encouraging increased awareness and surveillance from the other provinces. The sample 
is Gauteng biased, which is a limitation of the study, and it is believed that the underlying 
trends shown for all four Salmonella serotypes from this study are not a good 
representation of quinolone-resistant isolates from the entire country of South Africa. 
Another limitation of this study was the time and financial constraints which resulted in a 




All four Salmonella serotypes from our study showed a similar pattern of independent 
emergence of quinolone resistance. The PFGE results for all four serotypes revealed 
dendrograms resolved into a large number of PFGE types in relation to the number of 
analysed isolates. The large number of PFGE types per serotype suggests that there have 
been a various number of probable sources for the emergence of quinolone resistance for 
each respective serotype. This finding suggests that quinolone resistance for these four 
Salmonella serotypes is driven by a selective pressure, in this case the treatment 
strategies, more than the source of the isolate. The use of MLVA as a secondary 
technique to PFGE provided evidence that MLVA should be used as a method for 
evaluating PFGE results for both Salmonella Typhi and Salmonella Typhimurium. PFGE 
is subjective as it relies on the researcher to identify and mark resultant bands using a 
software package. This may lead to discrepancies in results within a lab and between 
collaborating labs. MLVA allows for a more objective analysis as the analysis is 
automated and the analysis parameters are adhered to by the machinery and computer 
system.  For Salmonella, PFGE remains the primary genotyping technique. Although it 
has been shown that MLVA exhibits a greater discriminatory power than PFGE 
(Lindstedt et al., 2003; Liu et al., 2003; Boxrud et al., 2007), the two techniques should 
be used to complement each other where available as the combination will probably best 
represent the sample population.  
 
The four study Salmonella serotypes also share a common combination of mechanisms of 
resistance. The major mechanism of resistance for all four serotypes was an over-active 
efflux system. An over-active efflux system in combination with gyrA and parC 
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mutations was identified as contributory mechanisms in all four serotypes. The 
combination of gyrA and parC mutations alone was insufficient to explain the 
quinolone-resistant nature of any of the sequenced Salmonella isolates. No individual 
gyrA or parC mutation could be isolated as a major role player in quinolone resistance in 
these Salmonella isolates. The isolates from this study that exhibited mutations in both 
gyrA and parC were not as resistant as isolates with just a gyrA mutation. parC mutations 
are infrequent in Salmonella and the mutations at position 57 of parC gene occurs outside 
of the QRDR (Hopkins et al., 2005). It has been suggested that parC mutations only 
occur as a result of exposure to increased levels of quinolones and that Salmonella select 
an over-active efflux system as the primary defense to quinolones and QRDR mutations 
occur as a secondary mechanism of resistance (Giraud et al., 2006). 
 
It has been established that gyrA mutations and an over-active efflux system are 
contributory mechanisms to quinolone resistance, as well as the fact that parC mutations 
will not occur without an initial gyrA mutation (Hopkins et al., 2005). This lends 
evidence to the thought that isolates resistant to nalidixic acid and that possess gyrA 
mutation(s), with or without an over-active efflux system, are precursors to isolates that 
may possess parC mutations. These resultant isolates may be ciprofloxacin-resistant or 
may have a reduced susceptibility to ciprofloxacin. It may therefore be important to 
understand the relationship between parC mutations and an over-active efflux system. 
 
The final mechanism of quinolone resistance identified in our study was that of the 
plasmid gene qnrB. Plasmid-mediated quinolone resistance in Enterobacteriaceae has not 
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previously been described for any South African isolate. All four study Salmonella 
serotypes were screened for the presence of qnr plasmid genes with Salmonella Typhi, 
Salmonella Enteritidis and Salmonella Isangi isolates negative for all screened genes. The 
presence of the qnrB gene was identified in the most commonly isolated South African 
Salmonella serotype, Salmonella Typhimurium. Three isolates were positive for the qnrB 
gene. Two of the three isolates were ciprofloxacin-resistant with the qnrB found in 
combination with gyrA and parC mutations as well as an over-active efflux system in 
both isolates. The last of the three isolates was the only isolate from all the qnr screened 
studies isolates exhibiting a single mechanism of resistance. The isolate exhibited a 
low-level quinolone resistance which is indicative of the presence of the qnrB plasmid 
mediated resistance. Isolation of the qnrB plasmid in three out of one-hundred and 
twenty-nine total screened Salmonella isolates from our study highlights the fact that qnr 
plasmid mediated resistance remains rare amongst Salmonella serotypes (Hopkins et al., 
2007). 
 
Irrespective of the combination of the mechanisms of resistance for any of the analysed 
Salmonella isolates attention should not be drawn away from the important fact that these 
isolates were all nalidixic acid-resistant. Nalidixic acid-resistant isolates pose treatment 
challenges for healthcare professionals where the routine treatment for salmonellosis is 
ciprofloxacin. Although these isolates may be susceptible to ciprofloxacin according to 
the current CLSI breakpoints for ciprofloxacin, treatment of infection due to isolates 
resistant to nalidixic acid may result in treatment failure (Rupali et al., 2004). This is of 
particular concern with regard to the treatment of infection due to Salmonella Typhi as 
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the irresponsible use of ciprofloxacin has resulted in an increase in quinolone-resistant 
isolates. For example administering ciprofloxacin for the treatment of cholera, when it 
rehydration therapy has been shown to be the best treatment as antibiotics do not seem to 
decrease the duration or severity of illness (Oliphant & Green, 2002). The indiscriminate 
use of ciprofloxacin as a routine treatment has created an unfortunate selection pressure 
that the bacteria have responded to by developing mechanisms of resistance (Chitnis et 
al., 2006; Gupta and Kaur, 2008). Isolates that are nalidixic acid resistant are believed to 
exhibit a decreased susceptibility to ciprofloxacin. As a result subsequent treatment with 
ciprofloxacin could result in patients displaying a delayed response or may even lack a 
response to treatment (Hakanen et al., 2005). The CLSI breakpoints for ciprofloxacin are 
not accurately reflecting the true nature of the resistance patterns shown by the screened 
isolates (Crump et al., 2003). The CLSI breakpoints require review and nalidixic acid 
susceptibilities should be used as indicators of possible treatment failure with 
ciprofloxacin.  
 
The clinical importance of Salmonella Typhi and invasive Salmonella infection makes 
the understanding and evolution of antibiotic resistance trends, in respect to treatment of 
typhoid fever and invasive infection, of paramount importance. Little is known of the role 
of the AcrAB-TolC tripartite system of Salmonella in South Africa, but our work 
suggests it is important in these quinolone-resistant strains. Since the system may vary 
from strain to strain it is important to form a basis of understanding of the efflux system 
of local strains, as the efflux system may be the major contributory mechanism to 
quinolone resistance.  We have shown that an over-active efflux system in combination 
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with mutations in both gyrA and parC may play a major role in facilitating quinolone 
resistance in Salmonella Typhi, Salmonella Enteritidis and Salmonella Isangi. We have 
also shown that these mechanisms may be responsible for the quinolone resistance in the 
majority of the Salmonella Typhimurium isolates along with the rarely isolated 
mechanism of resistance, a qnr plasmid. Our study also highlights the need for further 
work to determine regional variability for gyrA mutations and to link the various 
mechanisms of resistance, such as, the relationship between parC mutations and an over-
active efflux system, as the significance of various mutations and their interactions 
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Appendix A: Pulsed-Field Gel Electrophoresis (PFGE) 
 
1M Tris 
121.1g Tris [Merck Ltd, Johannesburg, South Africa (Merck)] 
800ml deionized water 
Adjust to pH 8 with 1M HCl  
Adjust volume to 1000ml 
Sterilize the mixture by autoclaving 
 
1M HCl 
86.2ml HCl (Merck Chemicals, Darmstadt,Germany) 
913.8ml deionized water 
 
0.5M EDTA (pH 8) 
186.1g EDTA (disodium ethylenediaminetetra-acetic acid) (Merck) 
800ml deionized water 
Dissolve with the addition of sodium hydroxide pellets (Merck) 
Adjust to pH 8 
Adjust volume to 1000ml 




Cell suspension buffer (100mM Tris : 100mM EDTA, pH 8) 
10ml of 1M Tris, pH 8  
20ml of 0.5M EDTA, pH 8 
70ml deionized water 
Sterilize the mixture by autoclaving 
 
Proteinase-K (10mg/ml) 
200mg Proteinase-K [Roche Diagnostics GmbH, Mannheim, Germany (Roche)] 
20ml TE buffer 
Stored as 1000µl aliquots at ≈ -4ºC. 
 
SDS (10%) 
10g sodium dodecyl sulphate (Merck) 
100ml deionized water 
 
Cell lysis buffer (5ml/plug) 
0.5M EDTA, pH8 
1% N-lauroylsarcosine sodium salt (sarcosyl) [Sigma Chemical Co., St.Louis, MO, USA 
(Sigma)] 





Tris-EDTA (TE) buffer (10 mM Tris : mM EDTA, pH 8) 
10ml of 1M Tris, pH 8  
2ml of 0.5M EDTA, pH 8  
988ml deionized water 
Sterilize the mixture by autoclaving 
TBE
10Х TBE 
108g Tris (Merck) 
55g Boric acid (Merck) 
7.5g EDTA powder (Merck) or 40ml of 0.5M EDTA, pH 8 
Make up to 1000ml with deionized water 
Sterilize the mixture by autoclaving 
 
0.5Х TBE 
50ml 10Х TBE 
950ml deionized water 
 
1% SeaKem Gold® agarose 
1.5g SeaKem Gold® agarose (Cambrex Bio Science, Rockland,USA) 
150ml of 0.5Х TBE 





Ethidium bromide stock solution 
500mg ethidium bromide (Merck) 
50ml deionized water 
  
Ethidium bromide staining solution 
25µl of ethidium bromide (10mg/ml) 
250ml of 0.5X TBE 



















PCR primers used for Salmonella Typhi MLVA. 









PCR primers used for Salmonella Typhimurium MLVA. 













Appendix C: Polymerase Chain Reaction (PCR) and Sequencing 
Internal amplification control: 16SrRNA (726bp) 
 16SrRNA-primerB: GATTAGATACCCTGGTAGTCC 
 16SrRNA-r: ACGGCTACCTTGTTACGACTT 
C1 
Primers used for PCR and sequencing of the QRDR. 
Name Sequence (5' to 3') Product size (bp) 
stgyrA1 CGTTGGTGACGTAATCGGTA 251 
stgyrA2 CCGTACCGTCATAGTTATCC  
stmgyrB1 GCGCTGTCCGAACTGTACCT 181 
stmgyrB2 TGATCAGCGCCACTTCC  
stmparC1 CTATGAGATGTCAGAGCTGG 270 
stmparC2 TAACAGCAGCTCGGCGTATT  
stmparE1 TCTCTTCCGATGAAGTGCTG 240 
stmparE2 ATACGGTATAGCGGCGGTAG  
 
PCR reaction mix( 25µl reaction) 
1. Sterile deionized water                              17µl 
2. 10Х buffer with no MgCl2                         2.5µl 
3. MgCl2 (25mM)                                          1.5µl 
4. dNTP mix (25mM)                                       2µl 
5. Forward primer (20µM stock)                   0.5µl 
6. Reverse primer (20µM stock)                    0.5µl 
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7. Super-Therm DNA polymerase (5U/µl)    0.5µl 
8. Crude DNA template                                 0.5µl 
C2 
PCR primers used for qnr gene screening and sequencing. 
Name Sequence (5' to 3') Product size (bp) 
QP1 GATAAAGTTTTTCAGCAAGAGG 657 
QP2 ATCCAGATCGGCAAAGGTTA  
FQ1 ATGACGCCATTACTGTATAA 566 
FQ2 GATCGCAATGTGTGAAGTTT  
qnrS-F TGGAAACCTACAATCATACATATCG 585 
qnrS-R TTAGTCAGGATAAACAACAATACC  
 
C3 
Bromophenol blue (Loading buffer) 
0.25g bromophenol blue (Merck) 
40g sucrose (Merck) 
Dissolve in 100ml deionized water 
 
1.2% Agarose gel 
1.8g agarose (Whitehead Scientific, Johannesburg, South Africa) 
150ml of 1X TAE buffer 
Dissolve agarose in TAE 
Add 12µl ethidium bromide stock solution to molten agarose 
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TAE 
 10X TAE 
 48g Tris (Merck) 
 7.5g EDTA (Merck) 
 11ml of glacial acetic acid (Merck) 
 Adjust to a volume of 1000ml with deionized water 
 Sterilize the mixture by autoclaving 
 
 1X TAE (Running buffer) 
 100ml 10X TAE 
 900ml deionized water 
 Store at 2-8ºC 
  
C4 
Cycle sequencing reaction mix (≈15µl) 
1. Sterile deionized water                                                    6µl 
2. ABI Prism® Big-Dye Terminator reaction mix              3µl 
3. 5Х Buffer                                                                      1.5µl 
4. Single primer (forward or reverse-5µM)                         1µl 





Appendix D: Doubling Agar Dilution Minimum Inhibitory 
Concentration (MIC) and Efflux Pump Inhibition 
 
0.85% Saline 
8.5g Sodium chloride (Merck) 
1000ml of deionized water 
Sterilize the mixture by autoclaving 
 
1M Sodium hydroxide 
20g Sodium hydroxide (Merck) 
500ml of deionized water 
Sterilize the mixture by autoclaving 
 
Nalidixic acid (10mg/ml) 
200mg nalidixic acid powder [Abtek Biological Ltd. Liverpool, England (Abtek)] 
10ml of 1M Sodium hydroxide 
10ml of sterile deionized water 
Solution filtered through a filtered tip syringe and stored as 1000µl aliquots at ≈ -4ºC. 
 
Ciprofloxacin (1mg/ml) 
20mg ciprofloxacin powder (Abtek) 
20ml of sterile deionized water 
Solution filtered through a filtered tip syringe and stored as 1000µl aliquots at ≈ -4ºC. 
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Efflux pump inhibitor (10mg/ml) 
250mg β-Phe-Arg-naphthylamide (Sigma) 
25ml of sterile deionized water 
Solution filtered through a filtered tip syringe and stored as 1000µl aliquots at ≈ -4ºC. 
 
* All filtered solutions were passed through 0.45 micron Millex®-HV filter units 
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The molecular epidemiology and mechanism of quinolone resistance of South African 32 
human isolates of Salmonella Typhi received by the Enteric Diseases Reference Unit 33 
(EDRU) of the National Institute for Communicable Diseases for the period 2003-2007 34 
was investigated. Molecular epidemiology was investigated using pulsed-field gel 35 
electrophoresis (PFGE) analysis and multiple-locus variable-number tandem-repeats 36 
analysis (MLVA). Three probable mechanisms for quinolone resistance were investigated 37 
which included: amino acid mutations in the quinolone resistance determining regions 38 
(QRDRs) of DNA gyrase (gyrA/gyrB) and topoisomerase IV (parC/parE), active efflux 39 
of antibiotic out the bacterial cell and plasmid-mediated resistance encoded by qnr genes. 40 
For the period 2003-2007, 498 human isolates of Salmonella Typhi were received by the 41 
EDRU, of which 27 were resistant to nalidixic acid (MICs, ≥32 µg/ml) and susceptible to 42 
ciprofloxacin (MICs, ≤1 µg/ml). Only 19 of these quinolone-resistant isolates were 43 
available for analysis. These 19 isolates were genetically diverse as they could be 44 
differentiated into 5 PFGE types and 10 MLVA types, suggesting that quinolone-resistant 45 
strains have emerged independently of one another. All 19 isolates demonstrated the 46 
involvement of active efflux as a mechanism for resistance to nalidixic acid and reduced 47 
susceptibility to ciprofloxacin. All 19 isolates were negative for plasmid-mediated qnr 48 
resistance determinants. Seven isolates were investigated for mutations in the QRDRs of 49 
gyrA, gyrB, parC and parE. All seven isolates showed mutations in gyrA and parC. GyrA 50 
mutations were located at codons 81, 82, 83, 87 and 119; while parC mutations were 51 
located at codons 57 and 80. No mutations were shown in gyrB or parE. Our data show 52 
that active efflux of antibiotic out of the bacterial cell in combination with mutations in 53 
gyrA and parC, are the mechanisms responsible for quinolone resistance in South African 54 









Salmonella enterica is the leading cause of food and water-borne disease worldwide and 63 
the prevalence of antibiotic-resistant strains remains a serious public health concern (33). 64 
Salmonella enterica serotype Typhi (Salmonella Typhi) is one of over two thousand 65 
described serovars of Salmonella enterica and the causative agent of typhoid fever, and is 66 
transmitted via food or water contaminated with human faeces. The organism is of great 67 
clinical importance as humans are the only recognized reservoir of Salmonella Typhi 68 
(10). Salmonella Typhi infects an estimated twenty to thirty million individuals 69 
worldwide, resulting in an estimated four hundred thousand deaths annually. Infection 70 
occurs in individuals mainly in the age range five to fifteen years old. Infection rates in 71 
areas where typhoid fever is endemic may be as high as 1000 per 100 000 of population 72 
per year (10). Antibiotics are critical in the management of typhoid fever. Various 73 
fluoroquinolones such as ciprofloxacin have become routine treatment for typhoid fever 74 
(38). Internationally there has been a disturbing trend noted of increasing resistance to the 75 
fluoroquinolones in salmonellosis. Albayrak et al, 2004 (2) reported a 12.3% resistance 76 
rate to non-fluorinated quinolone nalidixic acid as well as reduced susceptibility to the 77 
fluoroquinolone ciprofloxacin, across a range of Salmonella serotypes including 78 
Salmonella Typhi. The value of nalidixic acid to predict a poor clinical response to 79 
ciprofloxacin-resistant strains has been recognized (1).  Incidence of elevated quinolone 80 
resistance rates in Salmonella have been reported from various countries around the 81 
world: 21.6% in Korea (6), 82.4% in Kenya (24) and 69% in Taiwan (11). Highlighting 82 
the global problem best may be the 2007 report from Nigeria where Doughari et al (34) 83 
found a 20% resistance rate to the fluorinated quinolone ciprofloxacin. Such elevated 84 
resistance rates among Salmonella species makes the management of infection due to 85 
Salmonella, in particular Salmonella Typhi due its clinical implications, all the more 86 
difficult. 87 
 88 
Three major mechanisms have been described for the development of quinolone 89 
resistance in Salmonella (12; 13; 20). The first mechanism involves amino acid mutations 90 
in the quinolone resistance determining regions (QRDRs) of DNA gyrase (gyrA/gyrB) 91 
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and topoisomerase IV (parC/parE) (13). DNA gyrase is the primary target of quinolone 92 
antibiotics. Amino acid mutations in the QRDR of gyrA results in resistance to the non-93 
fluorinated quinolone (12), nalidixic acid, while also resulting in reduced susceptibility to 94 
fluoroquinolones such as ciprofloxacin (13). Amino acid mutations at Ser-83 (to Phe, 95 
Tyr, or Ala) or at Asp-87 (to Gly, Asn, or Tyr) are the most frequently observed 96 
mutations in gyrA (11). Additional amino acid mutations in the QRDRs of parC, gyrB, 97 
and parE proteins, results in resistance to fluoroquinolones such as ciprofloxacin (13).The 98 
second mechanism for quinolone resistance in Salmonella is the active efflux of antibiotic 99 
from the bacterial cell. Efflux pumps are naturally present in bacteria and function to 100 
eliminate toxic compounds from the bacterial cell. Overproduction of efflux pumps 101 
results in removal of quinolones (and other antibiotics) from bacterial cells and 102 
contributes to the development of resistance (7).The AcrAB-TolC efflux system is a 103 
major player with regards to quinolone resistance in S. enterica. AcrAB is a member of 104 
the resistance nodulation cell division family of transporters and is encoded by acrAB (3; 105 
7). The pump has three components: a transporter protein in the inner membrane (AcrB), 106 
a periplasmic accessory protein (AcrA), and an outer membrane channel (TolC). AcrB 107 
captures its substrates within the phospholipid bilayer and transports them into the 108 
external medium via TolC. Cooperation between AcrB and TolC is mediated by the 109 
periplasmic protein AcrA (3).The involvement of the AcrAB-TolC efflux system in the 110 
development of quinolone resistance has been proven through studies which have taken 111 
quinolone-resistant strains, inactivated their efflux systems, and then showed a resultant 112 
decrease in resistance. Inactivation of efflux systems have been performed through 113 
inactivation of genes coding for the efflux (3) and through the use of efflux pump 114 
inhibitors such as Phe-Arg-naphthylamide (3; 36).The third mechanism described for the 115 
development of quinolone resistance in Salmonella is that of plasmid-mediated quinolone 116 
resistance (22; 26). Three genes have been identified as those responsible for conferring 117 
resistance to quinolones. The pentapeptide repeat gene qnrA is responsible for encoding a 118 
protein that protects DNA gyrase from inhibition by quinolones. The other pentapeptide 119 
repeat genes qnrB and qnrS have also been associated with conferring resistance to 120 
quinolones (20). 121 
 122 
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South Africa has an estimated burden of typhoid fever of 100 infections per 100 000 of 123 
population per year (10). In addition there exists areas in the eastern parts of the country 124 
with a reservoir of typhoid fever (39). In South Africa, molecular epidemiological data 125 
for Salmonella infections is limited. In this country very little data exists on the molecular 126 
basis for antibiotic resistance in Salmonella, apart from two recent studies describing the 127 
molecular basis for extended spectrum β-lactamase activity in South African S. enterica 128 
strains (16; 28). No study has yet undertaken a large scale genotypic analysis of South 129 
African human Salmonella strains isolated over a lengthy time period (years). 130 
 131 
The last few years have seen a rapid increase in the prevalence of nalidixic acid resistance 132 
amongst human isolates of S. enterica (31). In addition, ciprofloxacin-resistant isolates 133 
are increasingly being isolated (25). This increasing prevalence of quinolone resistance 134 
warrants an investigation into the molecular epidemiology and mechanism of resistance 135 
of quinolone-resistant S. enterica isolates in South Africa. In this study, we investigated 136 
the contribution of various molecular mechanisms to quinolone resistance in Salmonella 137 

















Material and Methods 154 
 155 
Bacterial strains: 156 
Four hundred and ninety eight Salmonella Typhi isolates were received at the Enteric 157 
Diseases Reference Unit (EDRU) of the National Institute for Communicable Diseases 158 
(NICD), of the National Health Laboratory Service, Sandringham, South Africa, between 159 
2003 and 2007 (25). Twenty seven of these 498 isolates were nalidixic acid-resistant 160 
[Minimum inhibitory concentration (MIC), ≥32 µg/mℓ], of which 19 nalidixic acid-161 
resistant isolates were available for molecular analysis. 162 
 163 
PFGE analysis: 164 
Pulsed-field gel electrophoresis (PFGE) analysis was utilized as our primary genotypic 165 
analysis method to investigate the genetic relatedness of all the strains. PFGE analysis 166 
was performed using a PulseNet standardized protocol (23) summarized as follows. 167 
Bacterial genomic DNA was digested with XbaI restriction endonuclease (Roche 168 
Diagnostics GmbH, Mannheim, Germany). For control purposes, a strain of Salmonella 169 
Braenderup, strain H9812 (21), was included as a reference standard and analyzed in 170 
parallel with all typhoid strains. Digested DNA was separated on a 1% agarose gel 171 
(SeaKem Gold agarose, Lonza, Rockland, ME, USA) using a CHEF-DR III 172 
electrophoresis system (Bio-Rad Laboratories Inc., Hercules, CA, USA) programmed 173 
with an electrophoresis gradient of 6 V/cm, an included angle of 120°, an initial switch 174 
time of 2.2 seconds, a final switch time of 63.8 seconds and a run time of 21 h. Following 175 
electrophoresis, agarose gels were stained with an ethidium bromide and patterns were 176 
visualized utilizing UV illumination. Images of the patterns were captured into 177 
BioNumerics (version 5.1) Software (Applied Maths, Sint-Martens-Latem, Belgium) for 178 
further analysis and comparison. All test patterns were normalized against the pattern of 179 
the Salmonella Braenderup reference standard. Cluster analysis of the patterns using the 180 
unweighted pair group method with arithmetic averages resulted in dendrograms, with 181 
analysis of banding patterns incorporating the Dice-coefficient at an optimization setting 182 
of 0.5% and a position tolerance setting of 1.5%. 183 
 184 
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Preparation of crude bacterial DNA: 185 
A small loopfull of bacteria (2 to 4 colonies) cultured on 5% blood agar (Diagnostic 186 
Media Products, Sandringham, South Africa) was resuspended into 400 µl of 10 mM Tris 187 
- 1 mM EDTA buffer (pH 8) and boiled at 95°C for 20 minutes. The suspension was then 188 
centrifuged at 12000 rpm for 3 minutes and the resulting supernatant (crude DNA 189 
preparation) was used as a template for PCR. 190 
 191 
MLVA: 192 
To supplement our PFGE outputs we used a second genotypic analysis method, multiple-193 
locus variable-number tandem-repeats (VNTRs) analysis (MLVA), to further analyze 194 
selected strains. MLVA was based on 3 VNTR gene loci (TR1, TR2 and TR3) as 195 
previously described (30). This method employed manual agarose gel electrophoresis 196 
analysis whereas we have revised the analysis method to incorporate automated capillary 197 
electrophoresis of fluorescently labelled PCR products. The makeup of PCR primers used 198 
to amplify VNTR loci are shown in Table 1. The forward primer for each locus was 199 
labelled with a distinctive fluorescent dye (Applied Biosystems, Foster City, CA, USA). 200 
Each VNTR locus was amplified in a separate PCR of 25 µl final volume containing 1 µl 201 
crude bacterial DNA, 2 mM MgCl2, 0.5 µM of each primer, 200 µM deoxynucleotide 202 
triphosphates (Bioline, London, UK), 1 U AmpliTaq Gold DNA polymerase (Applied 203 
Biosystems) and 1× AmpliTaq Gold DNA polymerase buffer (Applied Biosystems); with 204 
thermal cycling (25 times) at 95°C for 75 seconds, 55°C for 75 seconds and 72°C for 75 205 
seconds. The 3 resultant PCRs were pooled as follows: 2 µl of TR1 + 2 µl of TR2 + 6 µl 206 
of TR3. This pooled mixture was then diluted 1:40 in deionized water. Two µl of this 207 
diluted mixture was then mixed with 0.7 µl of GeneScan 600 LIZ size standard (Applied 208 
Biosystems) and 7.5 µl of Hi-Di formamide (Applied Biosystems). This 10 µl mixture 209 
was then incubated at 95°C for 3 minutes and cooled to room temperature before being 210 
subjected to capillary electrophoresis using an Applied Biosystems 3130 Genetic 211 
Analyzer. Electrophoresis was performed through POP-7 polymer (Applied Biosystems) 212 
at 15 kV for 25 minutes at a temperature of 60°C. Raw data was captured and analyzed 213 
using GeneMapper (version 4.0) software (Applied Biosystems) which identified each 214 
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VNTR locus by its distinctive colour (fluorescence) and automatically sized the gene 215 
product via comparison to the internal size standard. 216 
 217 
PCR and Sequencing of the QRDR: 218 
Seven isolates were selected for analysis. PCR was used to amplify the QRDR of gyrA, 219 
gyrB, parC and parE using previously described methods. Primers (Table 2) were 220 
synthesized by Inqaba Biotechnical Industries, Hatfield, South Africa. PCR was 221 
conducted using a Bio-Rad Thermal i-Cyler (Bio-Rad Laboratories Inc., Hercules, CA, 222 
USA) programmed for thermal cycling (30x) included a denaturation step of 95ºC for 1 223 
minute, a primer annealing step for 1 minute (52ºC for gyrA, 55ºC gyrB, 58ºC parC and 224 
57ºC parE) and a primer extension step at 72ºC for 30 seconds. PCR products were 225 
cleaned using Qiaquick PCR purification Kits (Qiagen). For DNA sequencing, PCR 226 
product was used as template in a PCR cycle sequencing reaction using the Big-Dye 227 
Terminator version 3.1 cycle sequencing kit (Applied Biosystems). Cycle sequencing 228 
products were subsequently analyzed on an Applied Biosystems 3130 Genetic Analyzer 229 
and a sequence was determined. Sequences resulting from the analysis of the quinolone-230 
resistant strains were compared to a quinolone-susceptible strain to determine mutations 231 
using BioEdit v.7.5 and the pairwise comparison tool EMBOSS 232 
(http://www.ebi.ac.uk/emboss/align/). 233 
 234 
PCR for qnr genes: 235 
Screening for qnrA, qnrB and qnrS was done on all nineteen isolates by PCR using 236 
previously described primers (Table 3) and methods (12; 22; 23). 237 
 238 
Antibiotic susceptibility testing and efflux pump screening: 239 
The MIC for nalidixic acid and ciprofloxacin of all nineteen isolates was determined by 240 
the Etest (AB Biodisk, Solna, Sweden) as instructed by the manufacturer; and by the 241 
doubling agar dilution method as previously described by the CLSI. The MIC breakpoints 242 
used were those recommended by the CLSI, and adjusted for increased accuracy of 243 
results (8; 9). The extra dilutions ranged from 1 µg/ml to 512 µg/ml for nalidixic acid and 244 
from 0.0625 µg/ml to 16 µg/ml ciprofloxacin. These agar dilution MICs were repeated 245 
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within the presence of 40 µg/ml Phe-Arg-naphthylamide (EPI), after conducting a pilot 246 
study to determine the appropriate concentration of EPI for efflux pump screening. This 247 


































PFGE analysis and MLVA: 281 
For PFGE analysis, all patterns showing ≥ 90% similarity on dendrogram were regarded 282 
as the same PFGE type. PFGE analysis of the 19 strains showed 5 PFGE types (Table 4). 283 
PFGE type 1 was represented by 2 strains. PFGE type 2 was the dominant PFGE type and 284 
was represented by 14 strains. Lastly, PFGE types 3, 4 and 5 were each represented by 1 285 
strain. MLVA of the 19 strains showed 10 MLVA types. MLVA was more 286 
discriminatory and was able to discriminate amongst strains showing the same PFGE 287 
type. For example, the cluster of strains constituting PFGE type 2 could be differentiated 288 
into 6 MLVA types (Table 4). 289 
 290 
Active Efflux: 291 
Etest susceptibility testing determined that all 19 strains were resistant to nalidixic acid 292 
(MIC ≥32 µg/mℓ) and susceptible to ciprofloxacin (MIC ≤1 µg/mℓ). These results were 293 
confirmed using the agar dilution method and results showed that nalidixic acid MICs for 294 
all the strains range from 128 µg/ml to ≥512 µg/ml, which confirmed their resistance to 295 
nalidixic acid. Agar dilution MICs for ciprofloxacin confirmed susceptibility with MICs 296 
of ≤0.5 µg/ml for all the strains. For all isolates, nalidixic acid and ciprofloxacin MICs 297 
were decreased when susceptibility testing was conducted in the presence of EPI. For 298 
nalidixic acid, the MICs decreased by either 16 or 32-fold; while for ciprofloxacin, the 299 
MICs decreased by either 2 or 8-fold. (Table 4). 300 
 301 
Mutations in gyrA and parC: 302 
All seven strains selected for QRDR PCR and sequencing exhibited some mutation in 303 
gyrA and parC. The gyrA mutations occurred at codons 81, 82, 83, 87 and 119; Gly81-304 
Ser, Asp82-Gly, Ser83-Phe/Ala/Met, Asp87-Cys and Ala119-Ser/Gly. The parC 305 
mutations occurred at codons 57 and 80; Tyr57-Ser/Gly/Ala, Ser80-Lys/Phe/Arg/Ile 306 




Mutations in gyrB and parE: 310 
This study revealed no mutations in either gyrB or parE. 311 
 312 
Plasmid-mediated quinolone resistance: 313 




























PFGE analysis was able to differentiate the 19 nalidixic acid-resistant strains into 5 PFGE 341 
types. However, MLVA was more discriminatory and differentiated the strains into 10 342 
MLVA types (Table 4). The superior discriminatory power of MLVA is illustrated within 343 
the PFGE type 2 cluster (14 strains), which MLVA is able to divide into 6 MLVA types. 344 
MLVA type 16 was the most common type accounting for eight out of the fourteen 345 
strains in the PFGE type 2 cluster. MLVA type 16, 15 and 17 only differ by a single 346 
allele (TR2) and may be considered under less strict circumstances as being identical. 347 
MLVA allows for a greater reproducibility and accuracy of result. The PFGE type 2 348 
cluster represents the majority of strains of which share a common ancestry. This 349 
immediately suggests that clonal spread of nalidixic acid resistance may have occurred. 350 
However QRDR sequencing data (discussed later) of selected strains within this PFGE 351 
type 2 cluster show completely different QRDR mutation profiles (Table 4). This would 352 
suggest that quinolone-resistant strains have emerged independently of one another, i.e. 353 
emergence of quinolone resistance in South African strains of Salmonella Typhi is not 354 
clonally driven. 355 
 356 
The investigation into the involvement of an active efflux revealed a 16 or 32-fold 357 
decrease in nalidixic acid MIC and a 2 or 8-fold decrease in ciprofloxacin MIC in the 358 
presence of EPI. This suggests that an active efflux pump is a major contributory factor in 359 
the quinolone resistance of these invasive Salmonella Typhi strains. An efflux pump as a 360 
mechanism of quinolone resistance has previously been observed in various Salmonella 361 
serotypes including Salmonella Typhi (14; 32). Baucheron et al illustrated the importance 362 
of the AcrB in fluoroquinolone resistance (3) and TolC in multidrug resistant Salmonella 363 
Typhimurium (5). Although the AcrAB-TolC efflux system may vary between strains 364 
(27) it has been shown that quinolone resistance is not as a result of one mechanism but 365 
due to a combination of mechanisms (18). We believe that a similar observation can be 366 
made for the South African strains. Gyrase mutations alone do not account for quinolone 367 
resistance in Salmonella as it is believed that AcrAB pump is the primary mechanism for 368 
fluoroquinolone resistance, especially if the QRDR mutations do not sufficiently explain 369 
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the resistant phenotype (3; 7). For South African strains, an active efflux is seen to be the 370 
major contributory mechanism to quinolone resistance; however it is not the only 371 
mechanism because even in the presence of EPI, 15 out of the 19 strains still show 372 
nalidixic acid resistance with MICs at 32 µg/mℓ (Table 4). The role of qnr plasmids can 373 
be excluded as screening for the pentapeptide repeat genes qnrA, qnrB and qnrS showed 374 
no positive results. This leaves mutations in the QRDR as the only other likely 375 
mechanism. 376 
 377 
Strains 200597, 235856, 185048 and 107432 show mutations at gyrA positions Ser83 378 
and/or Asp87, positions that have been previously described as important for quinolone 379 
resistance (18), therefore these mutations probably play a role in quinolone resistance in 380 
these strains. At these positions, novel mutations (Ser83-Met and Asp87-Cys) were 381 
observed in strain 185048. Some of our strains also show some novel mutations at novel 382 
positions in gyrA. Strain 113560 showed novel mutations at position 82 (Asp82-Gly) and 383 
position 119 (Ala119-Ser) of gyrA, strain 107432 also showed the novel Asp82-Gly 384 
mutation and strain 88972 also showed the novel Ala119-Ser mutation. For strains 385 
113560, 107432 and 88972, novel mutations at novel positions (Asp82 and Ala119) in 386 
gyrA may be operating as an alternative mechanism of resistance as compared to the 387 
commonly reported mutation at positions Ser83 and Asp87. Levy, et al (29) provided 388 
evidence to suggest that selection pressure in terms of the antibiotics the bacteria is 389 
exposed to, is a determining factor in the resulting mutations in gyrA. Treatment 390 
strategies for Salmonellosis differ for different regions and since quinolone-resistant 391 
Salmonella Typhi are rarely locally acquired in South Africa, the selection pressure may 392 
be driven by antimicrobial use in regions with elevated rates of Salmonella Typhi 393 
infection. Single point source mutations at codons 83 and 87 of the gyrA have over the 394 
years received much attention as the cause of quinolone resistance, in particular nalidixic 395 
acid and as a result linked to decreased susceptibility of fluoroquinolones (17; 37). 396 
Mutations in gyrA are normally associated with nalidixic acid resistance and seen as the 397 
precursors to mutations in the topoisomerase IV proteins parC and parE resulting in 398 
fluoroquinolone resistance or decreased susceptibility (1). Conversely it has been strongly 399 
suggested that multiple mutations in gyrA are more important in conveying 400 
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fluoroquinolone resistance than any respective combination of mutations in the gyrase 401 
and topoisomerase IV proteins. As important as mutations in gyrA are, these mutations 402 
themselves are not the defining contributory factor for quinolone resistance (12; 18). In 403 
the present study, sequencing analysis of nalidixic acid-resistant strains showed no amino 404 
mutations in either gyrB or parE. The two regions are homologous with the latter being 405 
the secondary target for quinolones (13). Mutations for both gyrB and parE remain rare 406 
for most Salmonella strains as most researchers report mainly on findings of gyrA 407 
mutations (19). The role of gyrB and parE in quinolone resistance is unclear (33), in 408 
particular gyrB, even in Salmonella strains exhibiting high levels of fluoroquinolone 409 
resistance (19). The present study showed that all nalidixic acid-resistant strains with 410 
amino mutations in gyrA, also showed amino acid mutations in parC. Mutation at 411 
position Ser80 of parC was commonly present and involved the mutation of Ser80 to 412 
either Phe or Arg or Lys or Ile. Some novel parC mutations were also identified and these 413 
included Tyr57-Gly, Tyr57-Ala, Ser80-Lys and Ser80-Phe. ParC mutation at positions 414 
Ser80 and Glu84 have previously been shown to be important for quinolone resistance 415 
(18). With regards the parC mutation at position Tyr57, Baucheron et al (4) suggested 416 
that mutation at this position (Tyr57-Ser) is not likely to be involved in quinolone 417 
resistance. Results from our study support this hypothesis. We found mutations at Tyr57 418 
for three of our strains. For one of these (strain 1647652), the mutation at position Ser80 419 
of parC was notably absent while a Tyr57-Ser mutation was present. With efflux 420 
inhibited, this strain was nalidixic acid-susceptible (MIC, 8 µg/ml), which would support 421 
the view that a mutation at position Tyr57 of parC is probably inconsequential. Overall, 422 
the role of parC mutations in quinolone-resistant Salmonella remains unclear. Our study 423 
suggests that mutation at position Ser80 of parC may be an important role player in 424 
quinolone resistance. The question remains concerning the role of mutations in both gyrA 425 
and parC. Our sequencing data from seven isolates showed mutations in both gyrA and 426 
parC. Based upon the results of previous studies (7; 18) we therefore expected that our 427 
isolates should be resistant to the fluoroquinolone, ciprofloxacin. However, we were 428 
surprised to find that our seven isolates were susceptible (MICs, ≤0.5 µg/ml) to 429 
ciprofloxacin. Our results are therefore in more agreement with the results of Eaves et al 430 
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(13) who found that isolates with mutations in both gyrA and parC were more susceptible 431 
to ciprofloxacin than isolates with mutations in gyrA alone. 432 
 433 
The clinical importance of Salmonella Typhi makes the understanding and evolution of 434 
antibiotic resistance trends, in respect to treatment of typhoid fever, of paramount 435 
importance. Little is known of the role of the AcrAB-TolC tripartite system of 436 
Salmonella Typhi in South Africa, but our work suggests it is important in these 437 
quinolone-resistant strains. Since the system may vary from strain to strain it is important 438 
to form a basis of understanding of the efflux system of local strains, as the efflux system 439 
may be the major contributory mechanism to quinolone resistance. We have shown that 440 
an active efflux system in combination with mutations in both gyrA and parC play a 441 
major role in facilitating quinolone resistance. Our study also highlights the need for 442 
further work to determine regional variability for gyrA mutations and to link the various 443 
mechanisms of resistance, as the significance of various mutations and their interactions 444 
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Table 1. PCR primers used for MLVA. 646 








Table 2. Primers used for PCR and sequencing of the QRDR. 648 










Table 3. PCR primers used for qnr gene screening. 650 









Table 4. PFGE types, MLVA types and MIC results for all Salmonella Typhi isolates as well as the QRDR results for seven selected isolates.     
           




type3 MLVA profile (TR1-TR2-TR3)4 gyrA mutations parC mutations 
Nalidixic acid agar 
dilution MIC (µg/ml)5 
Ciprofloxacin agar 
dilution MIC (µg/ml)5 Active Efflux 
92173 2005 GA 1 23 234 443 566   256 (8) 0.5 (0.0625) Yes 
113560 2006 WC 1 19 228 435 566 Asp82-Gly; Ala119-Ser Tyr57-Ala;Ser80-Phe 512 (32) 0.5 (0.0625) Yes 
1022834 2003 GA 2 25 214 000 566   512 (32) 0.5 (0.0625) Yes 
1028222 2004 GA 2 15 207 475 566   512 (32) 0.5 (0.0625) Yes 
1025746 2004 KZN 2 17 207 379 566   512 (32) 0.5 (0.0625) Yes 
1025656 2004 WC 2 17 207 379 566   512 (32) 0.5 (0.0625) Yes 
83959 2005 EC 2 16 207 000 566   512 (32) 0.5 (0.0625) Yes 
83947 2005 EC 2 16 207 000 566   256 (8) 0.5 (0.0625) Yes 
100247 2005 KZN 2 16 207 000 566   512 (32) 0.5 (0.0625) Yes 
1648788 2005 KZN 2 24 241 427 566   128 (8) 0.125 (0.0625) Yes 
152229 2006 GA 2 16 207 000 566   512 (32) 0.5 (0.0625) Yes 
107964 2006 WC 2 16 207 000 566   512 (32) 0.5 (0.0625) Yes 
107432 2006 WC 2 16 207 000 566 Asp82-Gly; Ser83-Ala Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
212418 2007 KZN 2 16 207 000 566   512 (32) 0.5 (0.0625) Yes 
185048 2007 WC 2 16 207 000 566 Ser83-Met; Asp87-Cys Tyr57-Gly; Ser80-Lys 512 (32) 0.5 (0.0625) Yes 
235856 2007 GA 2 22 207 395 566 Ser83-Ala Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
88972 2005 MP 3 18 261 000 542 Ala119-Gly Ser80-Ile >512 (32) 0.5 (0.0625) Yes 
1647652 2005 WC 4 21 241 000 566 Gly81-Ser; Asp82-Gly Tyr57-Ser 256 (8) 0.125 (0.0625) Yes 
200597 2007 KZN 5 18 261 000 542 Ser83-Phe Ser80-Arg 512 (32) 0.5 (0.0625) Yes 
      
1: GA, Gauteng; WC, Western Cape; KZN, KwaZulu-Natal; EC, Eastern Cape; MP, Mpumalanga.       
2: PFGE types based on relatedness as based on a dendrogram cluster analysis of the patterns using the unweighted pair group method with arithmetic averages, with analysis of banding patterns incorporating the Dice-coefficient at an 
optimization setting of 0.5% and a position tolerance setting of 1.5%. PFGE types defined at ≥90% similarity. 
3: MLVA types based on MLVA profiles.        
4: 000 represents no amplification of the PCR product at locus TR2.      
5: Value in parenthesis represents the MIC with the addition 40 µg/ml Phe-Arg-naphthylamide as an efflux pump inbihitor.    
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First Report of Plasmid-Mediated Quinolone Resistance in 1 
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To the Editor: Invasive infections with Salmonella species are usually treated with 19 
fluoroquinolones or extended spectrum β-lactams. Quinolone resistance results in 20 
reduced susceptibility to fluoroquinolones, leaving healthcare professionals with limited 21 
resources for treatment of salmonellosis. Three mechanisms contribute to quinolone 22 
resistance in Salmonella, (І) mutations in the quinolone resistant determining region 23 
(QRDR) genes (gyrA/gyrB) and topoisomerase IV genes (parC/parE) (1), (ΙΙ) active 24 
efflux of antibiotic out of the bacterial cell (1), and (ΙΙΙ) plasmid-mediated quinolone 25 
resistance encoded by qnr genes A, B and S (4). The qnr genes encode pentapeptide 26 
repeat proteins that block the action of ciprofloxacin on bacterial DNA gyrase and 27 
topoisomerase IV (7). The first qnr gene was isolated in 1998 from a Klebsiella 28 
pneumoniae isolate from Birmingham, Alabama, United States of America (8) and was 29 
called qnrA. Shewanella algae, an environmental species from marine and fresh water, 30 
was identified as its reservoir (10). qnrB is very similar to qnrA in that it confers low-31 
level quinolone resistance. qnr genes have been found in various bacteria worldwide 32 
which include; Citrobacter freundii, Enterobacter spp., Escherichia coli, K. Pneumoniae 33 
and Providencia stuartii in the United States (6), Salmonella species in the United 34 
Kingdom (4), and Shigella flexneri in Japan (3). We report on the first discovery of 35 
plasmid-mediated quinolone resistance in Enterobacteriaceae from South Africa, of 36 
which this was identified in a clinical isolate of Salmonella Typhimurium.  37 
 38 
 2 
A subset (48 isolates) of  invasive Salmonella Typhimurium isolates collected by the 39 
Enteric Diseases Reference Unit (EDRU) of the National Institute for Communicable 40 
Diseases (NICD) in the year 2006, with minimum inhibitory concentrations (MIC’s) to 41 
nalidixic acid of  ≥32µg/ml (as determined by E-tests), were screened for all known qnr 42 
genes using the polymerase chain reaction (PCR). Isolates which were PCR positive for a 43 
qnr gene, had their qnr and QRDR sequences determined. Agar dilution MIC’s for 44 
nalidixic acid and ciprofloxacin were conducted in the presence and absence of the efflux 45 
pump inhibitor, Phe-β-Arg-naphthylamide. 46 
 47 
For all isolates tested, we identified a single isolate (nalidixic acid MIC, 32µg/ml; 48 
ciprofloxacin MIC, 0.38 µg/ml) which was PCR positive for the qnrB (Figure 1). This 49 
isolate was cultured from a severely immunocompromised HIV seropositive 44 year old 50 
female. The patient presented to hospital with chronic diarrhea while being treated for 51 
military tuberculosis at an extended care facility. Her clinical condition was compounded 52 
by a history of previous alcohol dependency and her CD4 count was 31/µl. Her blood 53 
culture was positive for Salmonella Typhimurium. Stool culture did not yield an 54 
organism. The patient was treated empirically with a combination of ciprofloxacin 500mg 55 
bid, which was then continued for 14 days, and metronidazole 400mg tid. She recovered 56 
well. Antiretroviral therapy was initiated and she remains well 2 years later. 57 
 58 
The PCR positive qnrB result was confirmed by nucleotide sequence analysis of the 59 
gene. QRDR sequences for this isolate showed no mutations in any of the genes, so 60 
mutation in the QRDR was excluded as a mechanism for quinolone resistance. Agar 61 
dilution MIC’s for nalidixic acid and ciprofloxacin showed no involvement in resistance 62 
of an active efflux pump, as there was no difference in MIC values following testing in 63 
the absence or presence of an efflux pump inhibitor. The agar dilution MIC’s did 64 
illustrate the isolates low-level of nalidixic acid resistance (MIC, 32 µg/ml) and 65 
susceptibility to ciprofloxacin (MIC, 0.38 µg/ml). The low-level nalidixic acid resistance 66 
of this Salmonella Typhimurium can be attributed to the presence of the qnrB. In 67 
addition, the ciprofloxacin MIC of 0.38 µg/ml is seen by many as an increased MIC and 68 
the isolate may be described as having a reduced susceptibility to ciprofloxacin (5). 69 
 70 
Although the patient from whom the isolate was obtained recovered well after receiving 71 
ciprofloxacin therapy, isolates such as these, that confer low-level quinolone resistance 72 
due to qnr genes, facilitate the selection higher-level resistance mutants. The spread of 73 
high-level quinolone resistance amongst the serotype, Salmonella Typhimurium, as well 74 
as other Enterobacteriaceae is highly plausible as qnr genes are also found in combination 75 
with active efflux systems and QRDR mutated genes. Salmonella Typhimurium is the 76 
 3 
most common serotype isolated in South Africa (9), and South Africa has a high burden 77 
of HIV, so the isolation of plasmid-mediated quinolone resistance from an 78 
immunocompromised patient illustrates the possible treatment challenges for these 79 
patients when drug interactions have to be taken into consideration. Our study shows that 80 
the qnrB gene is a contributing factor for low-level quinolone resistance in Salmonella 81 
Typhimurium. This is the first report of any kind identifying the presence of qnr genes in 82 
South African Enterobacteriaceae isolates.  83 
 84 
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Figure 1: PCR amplification of the qnrB. Lane 1. Bioline Hypperladder ІV 100bp 125 
marker. Lane 2. First positive PCR for qnrB, product ≈ 560 bp. Lane 3. Confirmatory 126 
positive PCR for qnrB, product ≈ 560 bp. Lane 4. Negative control. Lane 5. Bioline 127 
Hypperladder ІV 100bp marker. 128 
 129 
 130 
 131 
 132 
 133 
